<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JHC</journal-id>
<journal-id journal-id-type="hwp">spjhc</journal-id>
<journal-title>Journal of Histochemistry &amp; Cytochemistry</journal-title>
<issn pub-type="ppub">0022-1554</issn>
<issn pub-type="epub">1551-5044</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1369/0022155411428469</article-id>
<article-id pub-id-type="publisher-id">10.1369_0022155411428469</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Breast and Ovarian Cancers</article-title>
<subtitle>A Survey and Possible Roles for the Cell Surface Heparan Sulfate Proteoglycans</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Yoneda</surname><given-names>Atsuko</given-names></name>
<xref ref-type="fn" rid="fn1-0022155411428469">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lendorf</surname><given-names>Maria E.</given-names></name>
<xref ref-type="fn" rid="fn1-0022155411428469">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Couchman</surname><given-names>John R.</given-names></name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Multhaupt</surname><given-names>Hinke A. B.</given-names></name>
</contrib>
</contrib-group>
<aff id="aff1-0022155411428469">Department of Biomedical Sciences, University of Copenhagen, Denmark</aff>
<author-notes>
<corresp id="corresp1-0022155411428469">Hinke A. B. Multhaupt, Department of Biomedical Sciences, BRIC, University of Copenhagen, Ole Maaløes Vej 5, 2200 Copenhagen N, Denmark E-mail: <email>hinke.multhaupt@bric.ku.dk</email></corresp>
<fn fn-type="other" id="fn1-0022155411428469">
<label>1</label>
<p>These authors contributed equally to the work.</p>
</fn>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2012</year>
</pub-date>
<volume>60</volume>
<issue>1</issue>
<fpage>9</fpage>
<lpage>21</lpage>
<history>
<date date-type="received">
<day>10</day>
<month>8</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>1</day>
<month>10</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© The Histochemical Society 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The Histochemical Society</copyright-holder>
</permissions>
<abstract>
<p>Tumor markers are widely used in pathology not only for diagnostic purposes but also to assess the prognosis and to predict the treatment of the tumor. Because tumor marker levels may change over time, it is important to get a better understanding of the molecular changes during tumor progression. Occurrence of breast and ovarian cancer is high in older women. Common known risk factors of developing these cancers in addition to age are not having children or having children at a later age, the use of hormone replacement therapy, and mutations in certain genes. In addition, women with a history of breast cancer may also develop ovarian cancer. Here, the authors review the different tumor markers of breast and ovarian carcinoma and discuss the expression, mutations, and possible roles of cell surface heparan sulfate proteoglycans during tumorigenesis of these carcinomas. The focus is on two groups of proteoglycans, the transmembrane syndecans and the lipid-anchored glypicans. Both families of proteoglycans have been implicated in cellular responses to growth factors and morphogens, including many now associated with tumor progression.</p>
</abstract>
<kwd-group>
<kwd>heparan sulfate proteoglycan</kwd>
<kwd>syndecan</kwd>
<kwd>glypican</kwd>
<kwd>carcinoma</kwd>
<kwd>glycosaminoglycan</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0022155411428469">
<title>Breast Cancer</title>
<sec id="section2-0022155411428469">
<title>Background</title>
<p>Breast cancer is the most frequently diagnosed cancer in women; one in four new cancers diagnosed worldwide each year is a cancer of the female breast. Breast cancer is also the leading cause of cancer-related death in women worldwide (<xref ref-type="bibr" rid="bibr44-0022155411428469">Kamangar et al. 2006</xref>; <xref ref-type="bibr" rid="bibr43-0022155411428469">Jemal et al. 2009</xref>; <xref ref-type="bibr" rid="bibr53-0022155411428469">La et al. 2010</xref>). Although multiple risk factors, such as old age, family history, and hormonal factors, have been identified, the etiology of the disease remains incompletely understood (<xref ref-type="bibr" rid="bibr30-0022155411428469">Dumitrescu and Shields 2005</xref>).</p>
<p>Carcinoma is the commonest malignant tumor of the breast. Ductal carcinoma in situ (DCIS) and invasive carcinoma are differentiated. Breast carcinomas are derived from the epithelial cells that line the terminal duct lobular unit. Cancer cells that remain within the basement membrane of the elements of the terminal duct lobular unit and the draining duct are classified as in situ or noninvasive. An invasive breast cancer is one in which there is dissemination of cancer cells outside the basement membrane of the ducts and lobules into the surrounding adjacent normal tissue. The most commonly used classification of invasive breast cancers divides them into ductal and lobular types. This classification was based on the belief that ductal carcinomas arose from ducts and lobular carcinomas from lobules. We now know that invasive ductal and lobular breast cancers both arise from the terminal duct lobular unit, and this terminology is no longer appropriate (<xref ref-type="bibr" rid="bibr84-0022155411428469">Sainsbury et al. 2000</xref>).</p>
<p>Breast cancer is not a single disease but is highly heterogeneous at both the molecular and clinical levels (<xref ref-type="bibr" rid="bibr76-0022155411428469">Perou et al. 2000</xref>; <xref ref-type="bibr" rid="bibr94-0022155411428469">Sorlie et al. 2001</xref>; <xref ref-type="bibr" rid="bibr12-0022155411428469">Bergamaschi et al. 2006</xref>; <xref ref-type="bibr" rid="bibr18-0022155411428469">Chin et al. 2006</xref>; <xref ref-type="bibr" rid="bibr101-0022155411428469">Vargo-Gogola and Rosen 2007</xref>). As a result, the dilemma facing clinicians who treat breast cancer patients has been for many years how to avoid overtreatment and undertreatment. Markers such as estrogen receptor (ER), progesterone receptor (PR), and epidermal growth factor receptor 2 (HER2) are currently used in the clinic for prognostic purposes as well as to stratify patients for appropriately targeted therapies (<xref ref-type="bibr" rid="bibr40-0022155411428469">Harvey et al. 1999</xref>; <xref ref-type="bibr" rid="bibr97-0022155411428469">Subramaniam and Isaacs 2005</xref>; <xref ref-type="bibr" rid="bibr83-0022155411428469">Ross et al. 2005</xref>; <xref ref-type="bibr" rid="bibr75-0022155411428469">Payne et al. 2008</xref>). Estimates suggest that treatment failure presently occurs in approximately 30% of breast cancer patients (<xref ref-type="bibr" rid="bibr69-0022155411428469">Mullan and Millikan 2007</xref>).</p>
</sec>
<sec id="section3-0022155411428469">
<title>Histopathology</title>
<p>Although several histologic types and subtypes of mammary carcinoma exist, &gt;95% are either ductal or lobular carcinoma (<xref ref-type="bibr" rid="bibr98-0022155411428469">Tavassoli 1999</xref>; <xref ref-type="bibr" rid="bibr80-0022155411428469">Rosen PP 2001</xref>). Both of these types of mammary carcinoma can be in situ and/or infiltrating, the difference being whether or not the neoplastic cells have invaded through the outer myoepithelial cells and into the surrounding intra- or interlobular stroma (<xref ref-type="bibr" rid="bibr80-0022155411428469">Rosen PP 2001</xref>). The majority (75%–80%) of mammary carcinomas are ductal carcinomas, whereas classic infiltrating lobular carcinoma (ILC) comprises 10% to 15% of all mammary carcinomas. Overall, ILC has a better prognosis compared with ductal carcinoma. The incidence of ILC has been steadily increasing over the past 20 years. Although the precise cause of this remains unknown, data support that it might be related to the use of hormone replacement therapy among postmenopausal women (<xref ref-type="bibr" rid="bibr56-0022155411428469">Li et al. 2003</xref>).</p>
<p>ER, PR, and HER2 status are three important molecular features of invasive breast carcinomas that have been identified during the past 30 years, and their evaluation by pathologists is now mandatory (<xref ref-type="bibr" rid="bibr3-0022155411428469">Allred 2010</xref>). ER and PR are growth-regulating nuclear transcription factors that are usually measured by immunohistochemistry (IHC), and the amount of protein expressed is directly related to responsiveness to endocrine therapy, which is why they are so important (<xref ref-type="bibr" rid="bibr40-0022155411428469">Harvey et al. 1999</xref>; <xref ref-type="bibr" rid="bibr66-0022155411428469">Mohsin et al. 2004</xref>). HER2 is a growth factor receptor (among other functions) at the cell membrane. Cell surface levels of this membrane protein strongly associate with amplification of this oncogene, and thus HER2 status can be measured either at the protein level by IHC or at the DNA level by assessing gene copy number with assays such as fluorescence in situ hybridization. Overexpressed and/or amplified HER2 is a relatively weak prognostic factor in untreated patients, but it is a strong predictive factor for responsiveness to targeted therapies such as trastuzumab, which is the primary reason for measuring it (<xref ref-type="bibr" rid="bibr82-0022155411428469">Ross et al. 2004</xref>; <xref ref-type="bibr" rid="bibr3-0022155411428469">Allred 2010</xref>).</p>
</sec>
</sec>
<sec id="section4-0022155411428469">
<title>Ovarian Cancer</title>
<sec id="section5-0022155411428469">
<title>Epidemiology and Risk Factors</title>
<p>Epithelial ovarian cancer is the leading cause of death among the gynecologic cancers and the fourth leading cause of cancer death in women in the United States (<xref ref-type="bibr" rid="bibr43-0022155411428469">Jemal et al. 2009</xref>). Incidence rates vary considerably but are highest in industrialized countries with the exception of Japan. Ovarian cancer is one-tenth as common as breast cancer but three times as lethal. The high mortality rate is generally attributed to its occult development, resulting in advanced, widespread disease occurring in approximately 75% of women at diagnosis. The overall 5-year survival rate of ovarian cancer is about 30%. However, in about 25% of women, disease is confined to the ovary (stage I), and 5-year survival is more than 90%, compared with 10% for women with advanced disease (<xref ref-type="bibr" rid="bibr21-0022155411428469">Christie and Oehler 2006</xref>; <xref ref-type="bibr" rid="bibr52-0022155411428469">Kurman et al. 2008</xref>). The incidence of epithelial ovarian cancer is age related and is generally a disease of postmenopausal women. Malignant epithelial tumors are most common between the ages of 40 and 60 years.</p>
<p>The molecular events leading to the development of epithelial ovarian cancer are not known currently. Epidemio-logically developed risk factors that have been identified include family history, null parity, early menarche and late menopause, increasing age, and residence in developed countries (<xref ref-type="bibr" rid="bibr24-0022155411428469">Daly and Obrams 1998</xref>). Most ovarian cancers are the result of sporadic mutations. Approximately 10% of cases are attributed to a familial disposition. Women who carry deleterious mutations of the BRCA1 or BRCA2 gene are the largest subset at risk for ovarian cancer. For women who have BRCA1 (17q21chromosome) mutations, the risk of ovarian cancer begins to rise in their late 30s and is estimated to result in a lifetime risk of 25% to 40% (<xref ref-type="bibr" rid="bibr41-0022155411428469">Hennessy et al. 2009</xref>). Women who carry BRCA2 (13q12 chromosome) gene mutations also are at substantial risk of developing ovarian cancer (15%–25%). BRCA1 and BRCA2 are tumor suppressor genes inherited in an autosomal dominant mode (<xref ref-type="bibr" rid="bibr86-0022155411428469">Schmeler et al. 2006</xref>).</p>
<p>Spread of ovarian cancer beyond the ovary occurs in three ways. First, the tumor can penetrate the ovarian capsule and directly invade contiguous organs. Second, the tumor cells may spread via the lymphatics involving the pelvic and para-aortic lymph nodes. Lymph node metastases occur in as many as 20% of early stage cancers and the majority of advanced-stage cancers. Third, ovarian cancer cells will escape from areas where the tumor has penetrated the capsule of the ovary and escape into the peritoneal cavity. This latter form of spread is the most devastating because it results in the dissemination of tumor cells throughout the peritoneal cavity (<xref ref-type="bibr" rid="bibr13-0022155411428469">Bharwani et al. 2011</xref>). Stage I tumor is limited to the ovaries, stage II tumor involves one or both ovaries with pelvic extension, stage III tumor involves one or both ovaries with confirmed peritoneal metastasis outside the pelvis and/or regional lymph node metastasis, and stage IV tumor is accompanied by distant metastasis (<xref ref-type="bibr" rid="bibr14-0022155411428469">Bhoola and Hoskins 2006</xref>).</p>
<p>Approximately 90% of primary malignant ovarian tumors are epithelial in origin (carcinomas). The remainder are germ cell or stromal tumors. Epithelial ovarian carcinomas are thought to arise from the ovarian surface epithelium or from surface epithelial inclusion cysts. Ovarian carcinomas are heterogeneous and are primarily classified by cell type into serous, mucinous, endometrioid, clear cell, and Brenner (transitional) tumors corresponding to different types of epithelia in the organs of the female reproductive tract. Serous tumors are the most common type of ovarian epithelial tumor, accounting for about 53% of cases (<xref ref-type="bibr" rid="bibr87-0022155411428469">Seidman and Kurman 2003</xref>). The tumors in each of the categories are further subdivided into three groups—benign, malignant, and intermediate (borderline tumor)—to reflect their behavior.</p>
<p>The pathogenesis of ovarian carcinoma is unknown because of the lack of a tumor progression model. Based on clinical, morphologic, and molecular genetic characteristics, a model of ovarian carcinogenesis has been proposed. In this model, there are two main pathways of tumorigenesis. In this model, type I and type II refer to pathways of tumorigenesis and are not specific histopathological terms (<xref ref-type="bibr" rid="bibr88-0022155411428469">Shih and Kurman 2004</xref>). Type I tumors include low-grade serous carcinoma, mucinous carcinoma, endometrioid carcinoma, malignant Brenner tumors, and clear cell carcinoma. Type II tumors are composed of what are currently classified as moderately and poorly differentiated serous carcinoma (high-grade serous carcinoma), malignant mixed mesodermal tumors (carcinosarcomas), and undifferentiated carcinoma. The tumorigenic pathway for type I tumors resembles the adenoma-carcinoma sequence in colorectal cancer. They tend to present as stage I, low-grade neoplasms that develop in a stepwise manner from well-recognized precursors—namely, borderline tumors that in turn develop from cystadenomas and adenofibromas. They behave in an indolent fashion (<xref ref-type="bibr" rid="bibr10-0022155411428469">Bell DA 2005</xref>).</p>
<p>Type I tumors evolve slowly and are associated with distinct molecular changes that are rarely found in type II tumors. These low-grade tumors are relatively genetically stable and are characterized by mutations in a number of genes. The best characterized molecular alterations are sequence mutations in <italic>KRAS, BRAF</italic>, and <italic>ERBB2</italic> oncogenes. Previous studies have demonstrated that <italic>KRAS</italic> mutations occur in 35% of low-grade serous carcinomas and 33% of borderline tumors but not in high-grade serous carcinomas. Similarly, <italic>BRAF</italic> mutations occur in 30% of low-grade serous carcinomas and 28% of borderline tumors but not in high-grade serous carcinomas (<xref ref-type="bibr" rid="bibr90-0022155411428469">Singer et al. 2003</xref>). Mutations in <italic>ERBB2</italic> occur in less than 5% of these tumors. Mutations in <italic>KRAS, BRAF</italic>, and <italic>ERBB2</italic> are mutually exclusive. Therefore, mutations in these genes are detected in about two-thirds of type I tumors. The most common molecular genetic alteration in mucinous tumors is point mutations of <italic>KRAS</italic> (<xref ref-type="bibr" rid="bibr38-0022155411428469">Gemignani et al. 2003</xref>). In endometrioid carcinomas, mutation of β-catenin has been reported in approximately one-third of cases and mutation of <italic>PTEN</italic> in 20%. <italic>PTEN</italic> mutations rising to 46% have been seen in those tumors with 10q23 loss of heterozygosity (<xref ref-type="bibr" rid="bibr47-0022155411428469">Kim et al. 2008</xref>).</p>
<p>In contrast, type II tumors evolve rapidly. They nearly always present as high-stage, high-grade tumors that metastasize early in their course and are extremely aggressive (<xref ref-type="bibr" rid="bibr52-0022155411428469">Kurman et al. 2008</xref>). Type II carcinomas are rarely associated with morphologically recognizable precursor lesions, and it has been proposed that they develop de novo from the surface epithelium or inclusion cysts of the ovary (<xref ref-type="bibr" rid="bibr11-0022155411428469">Bell KA and Kurman 2000</xref>). The only mutation that has been consistently detected in type II tumors are mutations in <italic>TP53</italic>, which are very rare in type I tumors. In addition, type II tumors are characterized by considerable genetic instability, which is not observed in type I tumors.</p>
</sec>
</sec>
<sec id="section6-0022155411428469">
<title>Heparan Sulfate: A Very Complex Carbohydrate</title>
<p>All mammalian tissues contain heparan sulfate, and virtually all cells synthesize this glycosaminoglycan. The only notable exception is erythrocytes. Therefore, given the ubiquitous distribution of this carbohydrate and its ability to bind and concentrate many tumor-related growth factors, cytokines, and morphogens (<xref ref-type="bibr" rid="bibr37-0022155411428469">Fuster and Esko 2005</xref>), as well as regulate cell adhesion and migration through association with adhesion receptors, interest in heparan sulfate has intensified over the past decade.</p>
<p>Heparan sulfate is synthesized in the Golgi apparatus and always attached to a core protein; it is apparently never secreted as a free glycosaminoglycan. A variety of core proteins can bear heparan sulfate chains, covalently attached through specific serine residues. Many occur on the cell surface and are represented mainly by two families, the transmembrane syndecans and glycosylphosphatidylinositol (GPI)–anchored glypicans. Both are ancient families, represented in invertebrates, including <italic>Caenorhabditis elegans</italic> and <italic>Drosophila</italic> (<xref ref-type="bibr" rid="bibr22-0022155411428469">Couchman 2003</xref>, <xref ref-type="bibr" rid="bibr23-0022155411428469">2010</xref>; <xref ref-type="bibr" rid="bibr33-0022155411428469">Esko and Selleck 2002</xref>; <xref ref-type="bibr" rid="bibr48-0022155411428469">Kirkpatrick and Selleck 2007</xref>; <xref ref-type="bibr" rid="bibr58-0022155411428469">Lin X 2004</xref>; <xref ref-type="bibr" rid="bibr73-0022155411428469">Mythreye and Blobe 2009</xref>). In addition, there are basement membrane and matrix heparan sulfate proteoglycans (HSPGs), such as perlecan, type XVIII collagen, and agrin (<xref ref-type="bibr" rid="bibr42-0022155411428469">Iozzo et al. 2009</xref>). Heparan sulfate is a highly complex carbohydrate, perhaps the most complex known. The stem structure of xylose–galactose–galactose–uronic acid (from reducing terminus) is then followed by repeating disaccharides of glucosamine and uronic acid (<xref ref-type="fig" rid="fig1-0022155411428469">Figure 1</xref>). The complexity lies in subsequent modifications of the chains. These are sequential and commence with <italic>N</italic>-deacetylation and <italic>N</italic>-sulfation of the glucosamine residues. Some of the adjacent uronic acid residues are then epimerized from glucuronic to iduronic acid, of which many are then 2-<italic>O</italic>-sulfated. Then follow 6-<italic>O</italic>-sulfation and, to a lesser extent, 3-<italic>O</italic>-sulfation of the hexosamine residues to yield mature chains. However, for many proteoglycans, none of these modification proceeds to completion. The result is a chain that has regions of low sulfation and modification, alternating with regions of higher sulfation, often with intermediate sulfation at the boundaries of the subdomains (<xref ref-type="bibr" rid="bibr72-0022155411428469">Murphy et al. 2004</xref>). It is the higher sulfated regions that interact with peptide ligands, such as growth factors and extracellular matrix molecules. It seems clear that the pattern of heparan sulfate modification is not random but controlled by the cell, although how the transferases are organized in the Golgi apparatus to achieve this complexity is unknown. This is all the more impressive given that there are 12 different possible sulfated disaccharides (<xref ref-type="bibr" rid="bibr45-0022155411428469">Karamanos et al. 1996</xref>). Moreover, in mammalian cells, there are multiple transferase genes encoding proteins with ostensibly the same function. For example, there are four <italic>N</italic>-deacetylase/<italic>N</italic>-sulfotransferase genes, but they exhibit tissue-specific expression and show little redundancy (<xref ref-type="bibr" rid="bibr1-0022155411428469">Aikawa et al. 2001</xref>). Understanding the regulation of heparan sulfate synthesis remains a large challenge. There have been a few in-depth recent reviews of this area recently (<xref ref-type="bibr" rid="bibr51-0022155411428469">Kreuger et al. 2006</xref>; <xref ref-type="bibr" rid="bibr59-0022155411428469">Lindahl and Li 2009</xref>; <xref ref-type="bibr" rid="bibr91-0022155411428469">Skidmore et al. 2008</xref>).</p>
<fig id="fig1-0022155411428469" position="float">
<label>Figure 1.</label>
<caption><p>Heparan sulfate (HS) biosynthesis. HS synthesis involves sequential addition of <italic>N</italic>-acetylglucosamine and glucuronic acid (GlcA) residues to a tetrasaccharide linker region, which is covalently linked to the serine residue within the core protein GAG attachment site. Each sugar residue is depicted by a geometric symbol defined in the legend at the top left corner of the figure. The chain then undergoes stepwise modifications beginning with <italic>N</italic>-deacetylation and <italic>N</italic>-sulfation of some glucosamine residues. Adjacent to this first modification, some GlcA residues are epimerized to iduronic acid by a 5′ epimerase. Iduronate may then be 2-<italic>O</italic>-sulfated, with further sulfation on 6-<italic>O</italic> and 3-<italic>O</italic> positions on glucosamine residues. None of these modifications goes to completion, leading to a domain structure of HS chains with regions that are highly sulfated, flanked by regions of intermediate sulfation and low sulfation. Much more extensive chain modification is seen in the synthesis of the skeletal polysaccharide, heparin.</p></caption>
<graphic xlink:href="10.1369_0022155411428469-fig1.tif"/>
</fig>
<p>Further complexity arises on the cell surface. Both sulfatases and mammalian heparanase can be widespread. The former are specific for 6-<italic>O</italic>-sulfate residues of glucosamine, the latter cleaving the chains. Both affect cell behavior. Several studies have shown the significance of these enzymes on cellular responses, and both have been implicated in tumor progression (<xref ref-type="bibr" rid="bibr5-0022155411428469">Arvatz et al. 2011</xref>). Because some growth factor interactions and productive signaling can depend on specific sulfation motifs, it is not surprising that sulfatases can specifically alter some of these (<xref ref-type="bibr" rid="bibr68-0022155411428469">Morimoto-Tomita et al. 2005</xref>). Heparanase can be upregulated in a number of tumor cell types, again raising the prospect of altered cell behavior and a significant contribution to pathogenesis. From their detailed studies of heparan sulfate interactions with growth factors, <xref ref-type="bibr" rid="bibr8-0022155411428469">Backen et al. (2007)</xref> estimated that the activity of editing enzymes is of major significance in ovarian cancer.</p>
<sec id="section7-0022155411428469">
<title>Mammalian Syndecans: Multitasking Receptors</title>
<p>Syndecans are in some ways typical type I membrane receptors, with the added complication of attached glycosaminoglycan chains (<xref ref-type="bibr" rid="bibr23-0022155411428469">Couchman 2010</xref>; <xref ref-type="bibr" rid="bibr67-0022155411428469">Morgan et al. 2007</xref>). These are commonly heparan sulfate, and it is believed currently that syndecan core proteins are always substituted with at least one form of glycosaminoglycan (<xref ref-type="fig" rid="fig2-0022155411428469">Figure 2</xref>). Heparan sulfate chains can interact with a large array of ligands from many different classes of extracellular protein, including growth factors, morphogens, cytokines and chemokines, extracellular matrix molecules, clotting factors, and enzymes such as thrombin, metalloproteinases, and lipases. Techniques are not yet available to determine under what circumstances ligands bind in vivo, but despite what appears to be a complete lack of ligand specificity, knockouts of some transferases involved in heparan sulfate synthesis have specific and often lethal phenotypes (<xref ref-type="bibr" rid="bibr16-0022155411428469">Bishop et al. 2007</xref>). Heparan sulfate is required for multicellular animal life.</p>
<fig id="fig2-0022155411428469" position="float">
<label>Figure 2.</label>
<caption><p>Diagram of syndecans and glypicans. Schematic representations of human syndecan 1–4 monomers (A) and human glypican 1–6 (B) are shown.</p></caption>
<graphic xlink:href="10.1369_0022155411428469-fig2.tif"/>
</fig>
<p>The external core proteins, on which glycosaminoglycans are substituted, do not exhibit strong sequence homology between the four syndecans or even between species for the same syndecan. This led to an early speculation that the protein was nothing more than a carrier of carbohydrate chains, but this has had to be revised. For syndecan-1, -2, and -4 at least, the external core protein can trigger integrin-mediated cell adhesion events, which may be direct or, in the case of syndecan-4, probably indirect (<xref ref-type="bibr" rid="bibr23-0022155411428469">Couchman 2010</xref>). The mechanism of integrin involvement still remains to be elucidated, but conceivably this may happen in cis on the cell surface or in trans from an adjacent cell or, since syndecans can be shed, mediated by a soluble shed form. Syndecan shedding has been the subject of a recent review (<xref ref-type="bibr" rid="bibr63-0022155411428469">Manon-Jensen et al. 2010</xref>).</p>
<p>Cell adhesion comes to the fore again when considering cytoplasmic domains. Each of the four syndecans has been proposed to connect to the actin cytoskeleton (<xref ref-type="bibr" rid="bibr22-0022155411428469">Couchman 2003</xref>, <xref ref-type="bibr" rid="bibr23-0022155411428469">2010</xref>), through ezrin in syndecan-2 and α-actinin in the case of syndecan-4, to Src and its substrate, cortactin, in the case of syndecan-3. The cytoplasmic domains can be divided into three regions, two highly conserved in sequence across species and across the syndecans. The C1 region is membrane proximal, whereas C2 is distal and represents the carboxyl terminus. In between is a variable (V) region that is different across the syndecan members yet quite conserved across species within each syndecan. Likely, there are shared properties of the conserved (C) regions, whereas each V region has syndecan-specific functions. A small number of class II PDZ proteins can interact with C2 regions of syndecans (<xref ref-type="bibr" rid="bibr70-0022155411428469">Multhaupt et al. 2009</xref>), the most studied being syntenin and others being synectin (GIPC), synbindin, and CASK. Syntenin appears capable of binding all syndecans and may be involved with their intracellular trafficking (<xref ref-type="bibr" rid="bibr106-0022155411428469">Zimmermann et al. 2005</xref>).</p>
</sec>
<sec id="section8-0022155411428469">
<title>Signaling through Syndecans</title>
<p>The V regions of syndecans have been difficult to study, and this is perhaps because all syndecans form stable dimers, mediated in part by a GXXXG motif found within all syndecan transmembrane domains (<xref ref-type="bibr" rid="bibr27-0022155411428469">Dews and Mackenzie 2007</xref>). Furthermore, the cytoplasmic domains of syndecan-4 have been shown by NMR spectroscopy to form an unusual twisted clamp dimer, which is stabilized by interactions with the phospholipid PtdIns 4,5 P<sub>2</sub> (<xref ref-type="bibr" rid="bibr54-0022155411428469">Lee et al. 1998</xref>). In turn, this forms a complex with protein kinase Cα, which is then persistently activated (<xref ref-type="bibr" rid="bibr46-0022155411428469">Keum et al. 2004</xref>) and signals downstream to G proteins such as Rac and RhoA and on to rho kinases and actomyosin (<xref ref-type="bibr" rid="bibr23-0022155411428469">Couchman 2010</xref>; <xref ref-type="bibr" rid="bibr67-0022155411428469">Morgan et al. 2007</xref>). Syndecan-4 can therefore influence actin cytoskeletal architecture, and consistent with this, syndecan-4 can be incorporated into focal adhesions along with essential integrins (<xref ref-type="bibr" rid="bibr7-0022155411428469">Baciu and Goetinck 1995</xref>; <xref ref-type="bibr" rid="bibr23-0022155411428469">Couchman 2010</xref>; <xref ref-type="bibr" rid="bibr67-0022155411428469">Morgan et al. 2007</xref>; <xref ref-type="bibr" rid="bibr103-0022155411428469">Woods and Couchman 1994</xref>). Focal adhesions are important signaling organelles, involved with not only tight cell-extracellular matrix adhesion but also cell survival (<xref ref-type="bibr" rid="bibr29-0022155411428469">Dubash et al. 2009</xref>). Experiments with Chinese hamster ovary (CHO) cells have shown that overexpression of syndecan-4 can lead to increased focal adhesion assembly and reduced migration as a result (<xref ref-type="bibr" rid="bibr60-0022155411428469">Longley et al. 1999</xref>). It has long been known that focal adhesions, being points of stable cell-matrix interaction, oppose cell migration. However, fibroblasts from syndecan-4 knockout mice are also migration-defective in vitro and possibly in vivo because granulation tissue angiogenesis in skin wound healing is reduced (<xref ref-type="bibr" rid="bibr31-0022155411428469">Echtermeyer et al. 2001</xref>). It therefore seems as if efficient cell migration requires enough syndecan-4 but not too much. Elegant studies have also shown that syndecan-4 is also required for directional persistence of migration, a Rac-dependent process (<xref ref-type="bibr" rid="bibr9-0022155411428469">Bass et al. 2007</xref>). The underlying signaling control of these processes is not yet fully understood. However, by comparison, very little is understood about the other syndecan cytoplasmic domains, perhaps because oligomerization and structural constraints have to be satisfied before signaling complexes can be assembled. This is a challenge that needs to be met. Certainly, the connection between cell migration and possibly invasion may be a potent component of tumor cell progression.</p>
</sec>
<sec id="section9-0022155411428469">
<title>The Glypicans</title>
<p>The glypican family comprises six members (glypican 1–6) in human and mouse and two members (Dally and Dally-like protein [Dlp]) in <italic>Drosophila</italic>. The glypicans can be further divided into two groups based on sequence homology: (1) glypicans 1, 2, 4, and 6 and Dlp and (2) glypicans 3 and 5 and Dally (<xref ref-type="bibr" rid="bibr35-0022155411428469">Filmus et al. 2008</xref>). This family of cell surface HSPG is anchored through glycosylphosphatidylinositol in the outer layer of cell membranes. It has been shown that some members of glypicans, including glypican-3, can be processed by furin-like convertase, which favors binding of Wnt (<xref ref-type="bibr" rid="bibr26-0022155411428469">De Cat et al. 2003</xref>; <xref ref-type="bibr" rid="bibr35-0022155411428469">Filmus et al. 2008</xref>). Glypican can be detected in conditioned medium of cultured cells, but unlike syndecans, there are no reports of glypican shedding by proteases. Instead of shedding by proteases, glypicans can be released from cell membranes by the extracellular lipase Notum at the GPI anchor (<xref ref-type="bibr" rid="bibr50-0022155411428469">Kreuger et al. 2004</xref>). Heparan sulfate attachment sites on glypicans are predominantly located close to the cell membrane. There are no similarities in structure between syndecans and glypicans, at least based on sequence comparisons. Glypicans usually have eight cysteine residues, indicative of a globular structure with four disulfide bridges.</p>
<p>Genetic interaction experiments in <italic>Drosophila</italic> show that glypicans regulate bone morphogenetic protein (BMP), fibroblast growth factors (FGF), hedgehogs (Hh), and wingless (Wg), all of which have heparin-binding properties (<xref ref-type="bibr" rid="bibr35-0022155411428469">Filmus et al. 2008</xref>). Glypicans seem to regulate morphogen gradients in the extracellular matrix and the interaction of cytokines with other receptors by facilitating and/or stabilizing them. The contribution of glypican in FGF signaling is mainly mediated by heparan sulfate chains (<xref ref-type="bibr" rid="bibr92-0022155411428469">Song et al. 1997</xref>). However, molecular properties of glypicans other than heparan sulfate seem to be important for Wnt (<xref ref-type="bibr" rid="bibr93-0022155411428469">Song et al. 2005</xref>), Hh, and BMP because glypican-3 core protein can also interact with Hh (<xref ref-type="bibr" rid="bibr17-0022155411428469">Capurro et al. 2008</xref>).</p>
<p>In one case, glypican-3, there is a clear connection to a human genetic disease, Simpson-Golabi-Behmel syndrome (<xref ref-type="bibr" rid="bibr78-0022155411428469">Pilia et al. 1996</xref>). This is characterized by overgrowth, strongly suggesting that growth factor metabolism is altered, most likely that of Hh (<xref ref-type="bibr" rid="bibr17-0022155411428469">Capurro et al. 2008</xref>). In many cases, mutations lead to a secretion failure; the misfolded proteins accumulate intracellularly. Patients with this disease are prone to tumors, notably Wilms tumors of the kidney. The latest data suggest that the molecular basis for the disease lies in disrupted hedgehog signaling. Therefore, in Simpson-Golabi-Behmel syndrome, inappropriate Hh metabolism may lead to the overgrowth and tumor susceptibility. Certainly, the disease shows that there is no functional redundancy with respect to glypican-3 at least, because no other glypican can substitute.</p>
<p>Most evidence suggests that glypicans are important in growth factor and morphogen responses, whereas roles in cell adhesion seem to be the prerogative of syndecans. In <italic>Drosophila</italic>, there are two glypican genes and one syndecan (<xref ref-type="bibr" rid="bibr48-0022155411428469">Kirkpatrick and Selleck 2007</xref>; <xref ref-type="bibr" rid="bibr23-0022155411428469">Couchman 2010</xref>). Deletions and mutations in the glypicans Dally and Dally-like influence a number of growth factors (e.g. FGF, Wg, and Hh), whereas syndecan’s role in invertebrates has been shown to relate particularly to neural path finding and the Slit-Robo system (<xref ref-type="bibr" rid="bibr58-0022155411428469">Lin X 2004</xref>; <xref ref-type="bibr" rid="bibr96-0022155411428469">Steigmann et al. 2004</xref>).</p>
</sec>
<sec id="section10-0022155411428469">
<title>Glypicans in Breast and Ovarian Cancers</title>
<p>Because many growth factors are implicated in tumor progression and tumor angiogenesis, for example, it is not surprising that changes in glypican expression have been noted in several human tumors. Among the glypican family, GPC3/OCI-5/MXR7 has been well studied regarding cancer biology. The GPC3 gene is located at Xq26, a region frequently deleted in advanced ovarian cancers (<xref ref-type="bibr" rid="bibr19-0022155411428469">Choi C et al. 1998</xref>). Silencing of GPC3 gene is reported in ovarian cancer (<xref ref-type="bibr" rid="bibr57-0022155411428469">Lin H et al. 1999</xref>) and human breast cancer (<xref ref-type="bibr" rid="bibr104-0022155411428469">Xiang et al. 2001</xref>). The mechanism of GPC3 silencing was due, in part, to hypermethylation of the GPC3 promoter, especially in hormone receptor–negative tumors (<xref ref-type="bibr" rid="bibr105-0022155411428469">Yan et al. 2001</xref>). Ectopic expression of glypican-3 inhibited growth in 8 of 10 breast cancer cell lines (<xref ref-type="bibr" rid="bibr104-0022155411428469">Xiang et al. 2001</xref>). Other research reported that this proteoglycan induced apoptosis in breast cancer MCF7 cells but not in colorectal tumor cells, although heparan sulfate was not required for this activity (<xref ref-type="bibr" rid="bibr39-0022155411428469">Gonzalez et al. 1998</xref>). With ectopic expression of glypican-3 in the LM3 mammary tumor cell line, its contribution to increased apoptosis sensitivity induced by serum depletion was noted (<xref ref-type="bibr" rid="bibr77-0022155411428469">Peters et al. 2003</xref>). Collectively, these data suggest that glypican-3 can act as a negative regulator of breast cancer growth. In the case of ovarian cancer, expression of this HSPG was restored by treatment of cells with a demethylating agent, whereas ectopic glypican-3 expression inhibited ovarian cancer cell growth (<xref ref-type="bibr" rid="bibr57-0022155411428469">Lin H et al. 1999</xref>).</p>
<p>In contrast, glypican-1 is strongly expressed in human breast cancers but low in normal breast tissues (<xref ref-type="bibr" rid="bibr64-0022155411428469">Matsuda et al. 2001</xref>). In the same study, it was found that the expression of glypican-3 and -4 was only slightly increased in cancers by comparison with normal tissues, and glypican-2 and -5 were below the level of detection in both normal and cancer samples. Treatment of breast tumor cells MDA-MB-231 and MDA-MB-468 with phosphoinositide-specific phospholipase C to release glypicans abrogated the mitogenic response to two heparin-binding growth factors, HB-EGF and FGF2 but not IGF-1. Reduction of glypican-1 protein level markedly decreased the mitogenic response to these growth factors as well as that to heregulin α, heregulin β, and hepatocyte growth factor (HGF). However, loss of mitogenic responsiveness to these growth factors in these clones was not due to altered syndecan-1 mRNA expression. A study by Lander’s group (<xref ref-type="bibr" rid="bibr28-0022155411428469">Ding et al. 2005</xref>) may resolve the molecular mechanism in the case of FGF2. Using pancreatic cancer cells, it was shown that treatment of cancer cells with FGF2 induced shedding of syndecan-1 and converted the FGF2 response to glypican dependent. This shedding was observed in the breast carcinoma MDA-MB-468 line as well. In pancreatic cancer cells, syndecan-1 shedding was MMP-7 dependent, which is a heparin-binding molecule itself and anchored to cells by HSPG (<xref ref-type="bibr" rid="bibr28-0022155411428469">Ding et al. 2005</xref>). It was also reported that ectopic expression of glypican-3 in mammary tumor cells also prevented the increase of MMP-2 induced by insulin-like growth factor II (IGF-II) (<xref ref-type="bibr" rid="bibr77-0022155411428469">Peters et al. 2003</xref>).</p>
<p>The same trend with both syndecan-1 and glypican-1 has been recorded for ovarian cancer, and their upregulation is a poor prognostic factor. This also applies to stromal localization of the two proteoglycans (<xref ref-type="bibr" rid="bibr25-0022155411428469">Davies et al. 2004</xref>). The relevance of other glypican members in ovarian carcinoma is not well understood. One report indicates that glypican-3 is absent or undetectable in the vast majority of clear cell, serous, endometrioid, and mucinous tumors (<xref ref-type="bibr" rid="bibr32-0022155411428469">Esheba et al. 2008</xref>). A second report, however, suggested that around 18% of ovarian carcinomas were glypican-3 positive, these being of the clear cell type (<xref ref-type="bibr" rid="bibr95-0022155411428469">Stadlmann et al. 2007</xref>). However, even where expressed, there was no association with tumor stage. Positive staining for this glypican was noted in a proportion of recurrent cases but not associated with chemoresponse.</p>
<p>Clear cell carcinoma occurs more frequently in Japan than in Western countries, and two early studies with small numbers of cases yielded conflicting results regarding glypican-3 expression in clear cell adenocarcinoma of the ovary (<xref ref-type="bibr" rid="bibr95-0022155411428469">Stadlmann et al. 2007</xref>; <xref ref-type="bibr" rid="bibr32-0022155411428469">Esheba et al. 2008</xref>). However, more recent studies focusing on clear cell carcinoma have been performed in Japan. GPC3 was expressed in about 40% of clear cell carcinomas (<xref ref-type="bibr" rid="bibr62-0022155411428469">Maeda et al. 2009</xref>; <xref ref-type="bibr" rid="bibr100-0022155411428469">Umezu et al. 2010</xref>) but rare in other types such as mucinous, endometrioid, or serous (<xref ref-type="bibr" rid="bibr62-0022155411428469">Maeda et al. 2009</xref>). One study showed that glypican-3 was significantly associated with poor overall survival in stage III/IV clear cell adenocarcinoma cases (<xref ref-type="bibr" rid="bibr62-0022155411428469">Maeda et al. 2009</xref>), whereas another study showed association with poor progression-free survival in stage I clear cell carcinoma patients (<xref ref-type="bibr" rid="bibr100-0022155411428469">Umezu et al. 2010</xref>). Both studies showed no correlations between its expression and clinicopathological factors (<xref ref-type="bibr" rid="bibr62-0022155411428469">Maeda et al. 2009</xref>; <xref ref-type="bibr" rid="bibr100-0022155411428469">Umezu et al. 2010</xref>). Stromal expression of glypican-1 was associated with a poor prognosis in ovarian cancers (<xref ref-type="bibr" rid="bibr79-0022155411428469">Ricciardelli and Rodgers 2006</xref>; <xref ref-type="bibr" rid="bibr25-0022155411428469">Davies et al. 2004</xref>).</p>
</sec>
<sec id="section11-0022155411428469">
<title>Syndecans in Breast and Ovarian Carcinoma</title>
<p>Most data relating to syndecans in these tumors concern syndecan-1. This proteoglycan has a predominantly epithelial distribution, so it has been studied in many carcinomas. Upregulation at the protein and mRNA levels has been recorded in breast oncogenesis and correlates with higher histological tumor grade, as well as increased mitotic index and tumor size, and therefore is a poor prognostic factor (<xref ref-type="bibr" rid="bibr55-0022155411428469">Lendorf et al. 2011</xref>). This last feature is common with ovarian carcinoma, but it is not universally true for all tumor types. Decreased expression and possible inhibitory functions have been suggested in lung, colorectal, and cervical cancers (<xref ref-type="bibr" rid="bibr4-0022155411428469">Antonnen et al. 2001</xref>; <xref ref-type="bibr" rid="bibr36-0022155411428469">Fujiya et al. 2001</xref>; <xref ref-type="bibr" rid="bibr61-0022155411428469">Lundin et al. 2005</xref>; <xref ref-type="bibr" rid="bibr89-0022155411428469">Shinyo et al. 2005</xref>). In the Wnt-1 expression model of mammary tumorigenesis in the mouse, syndecan-1 was shown to be essential because knockout mice were resistant (<xref ref-type="bibr" rid="bibr2-0022155411428469">Alexander et al. 2000</xref>). This suggests a role for syndecan-1, either directly or indirectly, in Wnt signaling, but it is also interesting that in this model, there is no redundancy. Presumably, syndecan-4 and some glypicans were present in the mammary epithelia but were unable to substitute for syndecan-1.</p>
<p>Syndecan-4 is also present in mammary epithelium but at lower levels than syndecan-1. It has not been intensively studied in either breast or ovarian cancer, and there are some differences in conclusions. One report shows that syndecan-4 and -1 are similar in breast cancer tissue, with increased expression being a poor prognostic indicator (<xref ref-type="bibr" rid="bibr6-0022155411428469">Baba et al. 2006</xref>). However, a second report suggests downregulation of syndecan-4 in malignant breast tissue (<xref ref-type="bibr" rid="bibr71-0022155411428469">Mundhenke et al. 2002</xref>). Our own study suggests that there is not a correlation between syndecan-4 expression and tumor type or grade. Rather, there was a correlation with expression of estrogen and progesterone receptor status (<xref ref-type="bibr" rid="bibr55-0022155411428469">Lendorf et al. 2011</xref>). Given that treatment options for patients with receptor-positive status are wider, this could indicate a better prognosis. We also showed that stromal syndecan-4 was a rare feature across all breast carcinomas, unlike syndecan-1, which had a stromal expression that was strongly associated with a higher tumor grade (<xref ref-type="bibr" rid="bibr55-0022155411428469">Lendorf et al. 2011</xref>). Examples of syndecans-1 and -4 in ovarian and breast carcinoma are shown in <xref ref-type="fig" rid="fig3-0022155411428469">Figures 3</xref> and <xref ref-type="fig" rid="fig4-0022155411428469">4</xref>.</p>
<fig id="fig3-0022155411428469" position="float">
<label>Figure 3.</label>
<caption><p>Ovarian carcinoma immunostained for syndecan-1. Serous papillary carcinomas of the ovary, grade II (A) and grade III (B), were stained with mouse monoclonal antibodies against human syndecan-1. (A) The grade II tumor cells strongly express syndecan-1, as shown by the positive cytoplasm. Focal membranous staining is also visible (arrow). Note syndecan-1-positive endothelial cells in the blood vessels (double arrowheads) and positive infiltrating immunological cells in the tumor stroma (arrowhead). (B) Tumor cells of grade III ovarian serous carcinoma show overall strong cytoplasmic and focally nuclear staining for syndecan-1. Scale bar: 100 µm.</p></caption>
<graphic xlink:href="10.1369_0022155411428469-fig3.tif"/>
</fig>
<fig id="fig4-0022155411428469" position="float">
<label>Figure 4.</label>
<caption><p>Immunohistochemical staining of human breast tissues for syndecan-1 and syndecan-4. Tissue microarray containing cores of normal human breast (A and B; presented case is AR++, ER+, PR++, and Her2++), intraductal carcinoma (C and D; presented case is AR–, ER+++, PR–, and Her2+++), and invasive ductal carcinoma grade II (E and F; presented case is AR–, ER+, PR–, and Her2+++) and grade III (G and H; presented case is AR–, ER–, PR–, and Her2–) were stained with mouse monoclonal antibodies against human syndecan-1 and syndecan-4. (A) Normal human breast ducts show positive syndecan-1 staining in myoepithelial (arrowhead) and secretory cells (arrow). The positive staining is cytoplasmic as well as nuclear. Endothelial cells of the blood vessels as well as the stromal fibroblasts are also positive (double arrowheads). (B) Syndecan-4 staining shows a predominant nuclear staining pattern (arrow); in addition, the stromal fibroblasts and endothelial cells are also positive (double arrowheads). (C, D) Intraductal carcinoma of the breast has strong cytoplasmic expression of syndecan-1 (C), whereas the syndecan-4 staining is nuclear (D). (E) Invasive ductal carcinoma grade II tumor cells show cytoplasmic expression for syndecan-1 (arrowhead). (F) The tumor cells only show very weak nuclear staining for syndecan-4 (arrowhead); the normal ducts are strongly positive (arrow). (G) Invasive ductal carcinoma grade III shows positive syndecan-1 staining in the cytoplasm (arrowhead). (H) Syndecan-4 shows a nuclear staining pattern (arrowhead). Scale bar: 100 µm (A, B, E–H); 50 µm (C, D).</p></caption>
<graphic xlink:href="10.1369_0022155411428469-fig4.tif"/>
</fig>
<p>Syndecan-3 has not been reported widely with respect to either breast or ovarian carcinoma, but its aberrant upregulation in ovarian carcinoma-associated vasculature has been noted (<xref ref-type="bibr" rid="bibr25-0022155411428469">Davies et al. 2004</xref>). Syndecan-2, on the other hand, has been studied more extensively and its expression reported in ovarian carcinoma and several other tumor types such as lung cancer, osteosarcoma, mesothelioma, colorectal cancer, and brain tumors (<xref ref-type="bibr" rid="bibr99-0022155411428469">Theocharis et al. 2010</xref>). It has also been reported that its expression in breast carcinoma is regulated by estradiol, through the action of estrogen receptor α (<xref ref-type="bibr" rid="bibr49-0022155411428469">Kousidou et al. 2008</xref>). In particular, this syndecan has been suggested to be a promoter of tumor angiogenesis, and it may be strongly expressed in vascular tissues (<xref ref-type="bibr" rid="bibr34-0022155411428469">Fears et al. 2006</xref>). Several tissue culture studies also suggest that colon carcinoma cell expression of syndecan-2 leads to Rac-related increased invasive behavior (<xref ref-type="bibr" rid="bibr74-0022155411428469">Park et al. 2002</xref>; <xref ref-type="bibr" rid="bibr20-0022155411428469">Choi Y et al. 2010</xref>), perhaps through an ability to interact with many tumor progression–promoting growth factors. However, it is once again dangerous to generalize. Studies with osteosarcoma cells suggest that syndecan-2 may be inhibitory and promote cell death through apoptosis (<xref ref-type="bibr" rid="bibr65-0022155411428469">Modrowski et al. 2005</xref>).</p>
</sec>
</sec>
<sec id="section12-0022155411428469">
<title>Mutations in Syndecan and Glypican Core Proteins or in Enzymes That Contribute to Heparan Sulfate Synthesis and Editing</title>
<p>A number of mutations related to proteoglycans have been recorded in breast and ovarian cancer (<xref ref-type="table" rid="table1-0022155411428469">Table 1</xref>). Most have been identified in ovarian serous carcinoma, and the majority of these mutations lead to changes in amino acid sequence. These mutations involve not only the core proteins of syndecans and glypicans but also some enzymes that are involved in heparan sulfate synthesis or modification of the mature polysaccharide. Four mutations have been described in syndecan-1 and two in syndecan-2 from ovarian carcinoma patients. A single mutation in syndecan-3 core protein is presumably silent because no change in amino acid sequence would follow. The functional consequences of the syndecan-1 and -2 mutations are unknown currently but may influence expression. One mutation in syndecan-1 that predicts a glycine 36→alanine replacement is immediately N-terminal of the first serine-glycine dipeptide at which heparan sulfate chain attachment occurs. Substitution of heparan sulfate chains always occurs at these serine-glycine motifs, which are usually surrounded by acidic residues (<xref ref-type="bibr" rid="bibr22-0022155411428469">Couchman 2003</xref>; <xref ref-type="bibr" rid="bibr91-0022155411428469">Skidmore et al. 2008</xref>). The amino acid change is conservative, however, so it is unlikely to influence glycanation. Similarly, the valine 25→leucine mutation in syndecan-1 may not have much effect, being apparently a conservative change within the signal sequence. The consequence of amino acid changes at residues 154 and 155, located around midway in the ectodomain, is unclear because of a dearth of structural studies on syndecan ectodomains, but residue 155 is not strongly conserved across mammals.</p>
<table-wrap id="table1-0022155411428469" position="float">
<label>Table 1.</label>
<caption><p>Mutations in Genes Encoding Heparan Sulfate Proteoglycan Core Proteins and Heparan Sulfate Synthesis and Modification</p></caption>
<graphic alternate-form-of="table1-0022155411428469" xlink:href="10.1369_0022155411428469-table1.tif"/><table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="center"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Gene<sup><xref ref-type="table-fn" rid="table-fn2-0022155411428469">a</xref></sup></th>
<th align="center">Sample Name</th>
<th align="center">COSMIC Sample ID</th>
<th align="center">Amino Acid</th>
<th align="center">Nucleotide</th>
<th align="center">Primary Tissue</th>
<th align="center">Tissue Subtype</th>
</tr>
</thead>
<tbody>
<tr>
<td>SDC1</td>
<td>TCGA-13-1497</td>
<td>1474820</td>
<td>p.V25L</td>
<td>c.73G&gt;C</td>
<td>Ovary</td>
<td>serous_carcinoma</td>
</tr>
<tr>
<td/>
<td>TCGA-23-1124</td>
<td>1474818</td>
<td>p.G36A</td>
<td>c.107G&gt;C</td>
<td>Ovary</td>
<td>serous_carcinoma</td>
</tr>
<tr>
<td/>
<td>TCGA-24-1104</td>
<td>1474879</td>
<td>p.R155M</td>
<td>c.464G&gt;T</td>
<td>Ovary</td>
<td>serous_carcinoma</td>
</tr>
<tr>
<td/>
<td>TCGA-25-2409</td>
<td>1475063</td>
<td>p.H154Y</td>
<td>c.460C&gt;T</td>
<td>Ovary</td>
<td>serous_carcinoma</td>
</tr>
<tr>
<td>SDC2</td>
<td>TCGA-09-2053</td>
<td>1474995</td>
<td>p.V43G</td>
<td>c.128T&gt;G</td>
<td>Ovary</td>
<td>serous_carcinoma</td>
</tr>
<tr>
<td/>
<td>TCGA-23-1116</td>
<td>1475103</td>
<td>p.E125K</td>
<td>c.373G&gt;A</td>
<td>Ovary</td>
<td>serous_carcinoma</td>
</tr>
<tr>
<td>SDC3</td>
<td>TCGA-13-0724</td>
<td>1474935</td>
<td>p.E151E</td>
<td>c.453G&gt;A</td>
<td>Ovary</td>
<td>serous_carcinoma</td>
</tr>
<tr>
<td>GPC3</td>
<td>103947</td>
<td>1520563</td>
<td>p.R254*</td>
<td>c.760C&gt;T</td>
<td>Breast</td>
<td>basal_(triple-negative)_carcinoma</td>
</tr>
<tr>
<td>GPC5</td>
<td>TCGA-10-0926</td>
<td>1474976</td>
<td>p.R223C</td>
<td>c.667C&gt;T</td>
<td>Ovary</td>
<td>serous_carcinoma</td>
</tr>
<tr>
<td/>
<td>TCGA-23-1032</td>
<td>1474876</td>
<td>p.E365G</td>
<td>c.1094A&gt;G</td>
<td>Ovary</td>
<td>serous_carcinoma</td>
</tr>
<tr>
<td>SULF1</td>
<td>TCGA-09-2056</td>
<td>1474870</td>
<td>p.F168L</td>
<td>c.504C&gt;G</td>
<td>Ovary</td>
<td>serous_carcinoma</td>
</tr>
<tr>
<td/>
<td>TCGA-13-0760</td>
<td>1474815</td>
<td>p.Y838Y</td>
<td>c.2514T&gt;C</td>
<td>Ovary</td>
<td>serous_carcinoma</td>
</tr>
<tr>
<td>SULF2</td>
<td>BB12T</td>
<td>1235096</td>
<td>p.Y531H</td>
<td>c.1591T&gt;C</td>
<td>Breast</td>
<td>ductal_carcinoma</td>
</tr>
<tr>
<td/>
<td>HCC2157</td>
<td>1235084</td>
<td>p.D573N</td>
<td>c.1717G&gt;A</td>
<td>Breast</td>
<td>ductal_carcinoma</td>
</tr>
<tr>
<td/>
<td>TCGA-04-1350</td>
<td>1475091</td>
<td>p.R137W</td>
<td>c.409C&gt;T</td>
<td>Ovary</td>
<td>serous_carcinoma</td>
</tr>
<tr>
<td/>
<td>TCGA-09-2044</td>
<td>1474844</td>
<td>p.A128S</td>
<td>c.382G&gt;T</td>
<td>Ovary</td>
<td>serous_carcinoma</td>
</tr>
<tr>
<td>HPSE</td>
<td>TCGA-04-1347</td>
<td>1474821</td>
<td>p.V268I</td>
<td>c.802G&gt;A</td>
<td>Ovary</td>
<td>serous_carcinoma</td>
</tr>
<tr>
<td>HPSE2</td>
<td>TCGA-09-2056</td>
<td>1474870</td>
<td>p.K160I</td>
<td>c.479A&gt;T</td>
<td>Ovary</td>
<td>serous_carcinoma</td>
</tr>
<tr>
<td>EXT1</td>
<td>TCGA-13-0760</td>
<td>1474815</td>
<td>p.T568T</td>
<td>c.1704G&gt;A</td>
<td>Ovary</td>
<td>serous_carcinoma</td>
</tr>
<tr>
<td/>
<td>TCGA-20-0991</td>
<td>1474881</td>
<td>p.A151A</td>
<td>c.453G&gt;A</td>
<td>Ovary</td>
<td>serous_carcinoma</td>
</tr>
<tr>
<td>EXT2</td>
<td>107546</td>
<td>1520497</td>
<td>p.R86T</td>
<td>c.257G&gt;C</td>
<td>Breast</td>
<td>ER+PR+_carcinoma</td>
</tr>
<tr>
<td/>
<td>107546</td>
<td>1520497</td>
<td>p.?</td>
<td>c.536+1G&gt;C</td>
<td>Breast</td>
<td>ER+PR+_carcinoma</td>
</tr>
<tr>
<td>NDST2</td>
<td>TCGA-24-1558</td>
<td>1475081</td>
<td>p.E641D</td>
<td>c.1923G&gt;T</td>
<td>Ovary</td>
<td>serous_carcinoma</td>
</tr>
<tr>
<td>NDST4</td>
<td>TCGA-13-0801</td>
<td>1475076</td>
<td>p.G317R</td>
<td>c.949G&gt;C</td>
<td>Ovary</td>
<td>serous_carcinoma</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0022155411428469">
<p>Data from <ext-link ext-link-type="uri" xlink:href="http://www.sanger.ac.uk/genetics/CGP/cosmic/">http://www.sanger.ac.uk/genetics/CGP/cosmic/</ext-link>.</p>
</fn>
<fn id="table-fn2-0022155411428469">
<label>a</label>
<p>The genes encode for the following proteins: SDC1, syndecan-1; SDC2, syndecan-2; SDC3, syndecan-3; GPC3, glypican-3; GPC5, glypican-5; SULF1, sulfatase-1; SULF2, sulfatase-2; HPSE, heparanase-1; HPSE2, heparanase-2: EXT1, exostosin-1; EXT2, exostosin-2; NDST1, <italic>N</italic>-deacetylase/<italic>N</italic>-sulfotransferase-1; NDST2, <italic>N</italic>-deacetylase/<italic>N</italic>-sulfotransferase-2; NDST4, <italic>N</italic>-deacetylase/<italic>N</italic>-sulfotransferase-4).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The glutamate→lysine mutation in syndecan-2 reverses the charge at residue 125, which may have effects on folding or interactions. The replacement of valine with glycine at residue 43 of syndecan-2 is interesting because this residue immediately follows the first serine-glycine heparan sulfate substitution site. Whether it affects glycanation can be determined experimentally, but again this residue is not conserved, being replaced by leucine and alanine in rat and chicken, respectively. Most likely, there is no effect on heparan sulfate attachment to the core protein.</p>
<p>Of potential interest, two cases of glypican-5 mutation in ovarian serous carcinoma are now recorded. These mutations are in the central region of the core protein, and in one case, the mutation creates an unpaired cysteine residue, which may have a significant impact on the folding of the molecule and, perhaps, its interactions. It could be relevant to know whether these mutations affect expression on the cell surface, half-life, glycanation, or other functional attributes. There is also a single case of a mutation in glypican-3 in ductal carcinoma of the breast. This predicts a premature stop codon, and because this proteoglycan is known in other diseases to influence proliferation (<xref ref-type="bibr" rid="bibr17-0022155411428469">Capurro et al. 2008</xref>), this mutation may be important to study further.</p>
<p>The remaining mutations relevant to proteoglycans relate to heparan sulfate synthesis or its subsequent modification. EXT1 and 2 form a heterodimeric complex that is the major polymerase responsible for heparosan chain assembly. Two mutations from ovarian carcinoma in EXT1 are apparently silent, but that is not the case with the two EXT2 mutations identified in breast carcinoma patients (<xref ref-type="table" rid="table1-0022155411428469">Table 1</xref>). After chain assembly, many of the <italic>N</italic>-acetylglucosamine residues are modified by a combination of <italic>N</italic>-deacetylation and <italic>N</italic>-sulfation (<xref ref-type="fig" rid="fig1-0022155411428469">Fig. 1</xref>). Of the four human enzymes that carry out this dual function, single mutations in ovarian carcinoma are known in NDST2 and NDST4. The former leads to a conservative change in acidic residue, whereas the latter replaces a glycine with arginine. Whether this affects activity is unknown, but NDST4 is quite tissue restricted in distribution, and in many tissues, NDST1 is the major enzyme in terms of expression levels.</p>
<p>The sulfatases can selectively remove 6-<italic>O</italic>-sulfate groups from glucosamine residues, and Sulf2, in particular, is under scrutiny with respect to the progression of several tumor types (<xref ref-type="bibr" rid="bibr81-0022155411428469">Rosen SD and Lemjabbar-Alaoui 2010</xref>). This sulfatase is known to be upregulated in breast cancer (<xref ref-type="bibr" rid="bibr68-0022155411428469">Morimoto-Tomita et al. 2005</xref>). The effect of enzyme activity is to modify cellular responses to certain growth factors. Two mutations in Sulf1 and four in Sulf2 are known from breast and ovarian carcinomas, and in every case but one, this leads to changes in amino acids. Finally, heparanases are also under investigation in tumor biology because they cleave heparan sulfate chains to release bioactive oligosaccharides that may influence cell behavior (<xref ref-type="bibr" rid="bibr102-0022155411428469">Vlodavsky et al. 2011</xref>). Two mutations from ovarian carcinoma are recorded, but as with the Sulf mutations, what influence the amino acid substitutions have on enzymatic activity is unknown but potentially relevant to pursue.</p>
</sec>
<sec id="section13-0022155411428469">
<title>Conclusions and Perspectives</title>
<p>In both breast and ovarian carcinoma, there are changes in the expression and distribution of syndecans and glypicans. In some cases, these changes correlate significantly with poorer outcome. For example, in cases where syndecan-1 is present in the stroma of mammary tumors, there is a clear linkage to disease progression and tumor grade. Where this stromal syndecan-1 originates is not entirely clear, although likely it is of several sources, including the activated cancer-associated fibroblasts. Virtually nothing is known regarding possible alterations in heparan sulfate fine structure that may accompany these changes in proteoglycan expression. This may be relevant, given heparan sulfate’s ability to interact with many potent growth-promoting polypeptides.</p>
<p>Is the elevated presence of a proteoglycan, such as glypican-1 or syndecan-1, in tumors of significance as a contributor to tumor progression or merely an effect of elevated growth and increased invasive behavior? The answer is not clear, but the possible presence of mutations in syndecans and glypican-5 in ovarian cancer is intriguing. Moreover, syndecan-4 is known to be upregulated in cells bearing <italic>KRAS</italic> mutations, as is often seen in ovarian tumors (<xref ref-type="bibr" rid="bibr15-0022155411428469">Bild et al. 2006</xref>). It is tempting to believe that elevated levels of cell surface heparan sulfate are contributors to pathogenesis because their ability to interact with mitogenic peptides and act in co-receptor roles with high-affinity tyrosine kinase receptors puts this carbohydrate at a crucial place in cell communication. If we look across to myeloma, the evidence for a critical role of syndecan-1 seems certain (<xref ref-type="bibr" rid="bibr85-0022155411428469">Sanderson and Yang 2008</xref>). Circulating levels of shed syndecan-1 correlate with tumor progression, and experimental downregulation of the core protein led to much reduced proliferation of the tumor cells. It provides hope that a syndecan may form the basis of a therapeutic target for this devastating disease. In turn, these data suggest that cell surface proteoglycans in other tumors, including those highlighted here, may be important and relevant for further work. One key factor in their favor is that they are on the cell surface and are accessible targets. Only further work, particularly with animal models, will answer these key questions.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict">
<p>The authors declared no potential conflicts of interest with respect to the authorship and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure">
<p>The authors disclosed receipt of the following financial support for the research and/or authorship of this article: Support from The Danish National Research Foundation (HABM, JRC), Fabrikant Vilhelm Pedersen og Hustrus Legat through Novo Nordisk Fonden, Lundbeck Fonden, The Department of Biomedical Sciences at The University of Copenhagen (JRC), and Danish Cancer Research Foundation (AY) is gratefully acknowledged. MEL was supported by a Rota System PhD Fellowship from the Copenhagen Graduate School of Health Sciences.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aikawa</surname><given-names>J-I</given-names></name>
<name><surname>Grobe</surname><given-names>K</given-names></name>
<name><surname>Tsujimoto</surname><given-names>M</given-names></name>
<name><surname>Esko</surname><given-names>JD</given-names></name>
</person-group>. <year>2001</year>. <article-title>Multiple isoenzymes of heparan sulfate/heparin GlcNAc<italic>N</italic>-deacetylase/GlcN <italic>N</italic>-sulfotransferase</article-title>. <source>J Biol Chem</source>. <volume>276</volume>:<fpage>5876</fpage>–<lpage>5882</lpage>.</citation>
</ref>
<ref id="bibr2-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alexander</surname><given-names>CM</given-names></name>
<name><surname>Reichsman</surname><given-names>F</given-names></name>
<name><surname>Hinkes</surname><given-names>MT</given-names></name>
<name><surname>Lincecum</surname><given-names>J</given-names></name>
<name><surname>Becker</surname><given-names>KA</given-names></name>
<name><surname>Cumberledge</surname><given-names>S</given-names></name>
<name><surname>Bernfield</surname><given-names>M</given-names></name>
</person-group>. <year>2000</year>. <article-title>Syndecan-1 is required for Wnt-1 induced mammary tumorigenesis in mice</article-title>. <source>Nat Genet</source>. <volume>25</volume>:<fpage>329</fpage>–<lpage>332</lpage>.</citation>
</ref>
<ref id="bibr3-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Allred</surname><given-names>DC</given-names></name>
</person-group>. <year>2010</year>. <article-title>Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer</article-title>. <source>Mod Pathol</source>. <volume>23</volume>(<issue>Suppl 2</issue>):<fpage>S52</fpage>–<lpage>S59</lpage>.</citation>
</ref>
<ref id="bibr4-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Antonnen</surname><given-names>A</given-names></name>
<name><surname>Heikkila</surname><given-names>P</given-names></name>
<name><surname>Kajanti</surname><given-names>M</given-names></name>
<name><surname>Jalkanen</surname><given-names>M</given-names></name>
<name><surname>Joensuu</surname><given-names>H</given-names></name>
</person-group>. <year>2001</year>. <article-title>High syndecan-1 expression is associated with favourable outcome in squamous cell lung carcinoma treated with radical surgery</article-title>. <source>Lung Cancer</source>. <volume>32</volume>:<fpage>297</fpage>–<lpage>305</lpage>.</citation>
</ref>
<ref id="bibr5-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arvatz</surname><given-names>G</given-names></name>
<name><surname>Shafat</surname><given-names>I</given-names></name>
<name><surname>Levy-Adam</surname><given-names>F</given-names></name>
<name><surname>Ilan</surname><given-names>N</given-names></name>
<name><surname>Vlodavsky</surname><given-names>I</given-names></name>
</person-group>. <year>2011</year>. <article-title>The heparanase system and tumor metastasis: is heparanase the seed and soil?</article-title> <source>Cancer Metastasis Rev</source>. <volume>30</volume>:<fpage>253</fpage>–<lpage>268</lpage>.</citation>
</ref>
<ref id="bibr6-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baba</surname><given-names>F</given-names></name>
<name><surname>Swartz</surname><given-names>K</given-names></name>
<name><surname>van Eickhoff</surname><given-names>BR</given-names></name>
<name><surname>Zhang</surname><given-names>Y</given-names></name>
<name><surname>Wolberg</surname><given-names>W</given-names></name>
<name><surname>Friedl</surname><given-names>A</given-names></name>
</person-group>. <year>2006</year>. <article-title>Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype</article-title>. <source>Brest Cancer Res Treat</source>. <volume>98</volume>:<fpage>91</fpage>–<lpage>98</lpage>.</citation>
</ref>
<ref id="bibr7-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baciu</surname><given-names>PC</given-names></name>
<name><surname>Goetinck</surname><given-names>PF</given-names></name>
</person-group>. <year>1995</year>. <article-title>Protein kinase C regulates the recruitment of syndecan-4 into focal contacts</article-title>. <source>Mol Biol Cell</source>. <volume>6</volume>:<fpage>1503</fpage>–<lpage>1513</lpage>.</citation>
</ref>
<ref id="bibr8-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Backen</surname><given-names>AC</given-names></name>
<name><surname>Cole</surname><given-names>CL</given-names></name>
<name><surname>Lau</surname><given-names>SC</given-names></name>
<name><surname>Clamp</surname><given-names>AR</given-names></name>
<name><surname>McVey</surname><given-names>RM</given-names></name>
<name><surname>Gallagher</surname><given-names>JT</given-names></name>
<name><surname>Jayson</surname><given-names>GC</given-names></name>
</person-group>. <year>2007</year>. <article-title>Heparan sulphate synthetic and editing enzymes in ovarian cancer</article-title>. <source>Br J Cancer</source>. <volume>96</volume>:<fpage>1544</fpage>–<lpage>1548</lpage>.</citation>
</ref>
<ref id="bibr9-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bass</surname><given-names>MD</given-names></name>
<name><surname>Roach</surname><given-names>KA</given-names></name>
<name><surname>Morgan</surname><given-names>MR</given-names></name>
<name><surname>Mostafavi-Pour</surname><given-names>Z</given-names></name>
<name><surname>Schoen</surname><given-names>T</given-names></name>
<name><surname>Muramatsu</surname><given-names>T</given-names></name>
<name><surname>Mayer</surname><given-names>U</given-names></name>
<name><surname>Ballestrem</surname><given-names>C</given-names></name>
<name><surname>Spatz</surname><given-names>JP</given-names></name>
<name><surname>Humphries</surname><given-names>MJ</given-names></name>
</person-group>. <year>2007</year>. <article-title>Sydnecan-4-dependent Rac1 regulation determines directional migration in response to the extracellular matrix</article-title>. <source>J Cell Biol</source>. <volume>177</volume>:<fpage>527</fpage>–<lpage>538</lpage>.</citation>
</ref>
<ref id="bibr10-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bell</surname><given-names>DA</given-names></name>
</person-group>. <year>2005</year>. <article-title>Origins and molecular pathology of ovarian cancer</article-title>. <source>Mod Pathol</source>. <volume>18</volume>:<fpage>19</fpage>–<lpage>32</lpage>.</citation>
</ref>
<ref id="bibr11-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bell</surname><given-names>KA</given-names></name>
<name><surname>Kurman</surname><given-names>RJ</given-names></name>
</person-group>. <year>2000</year>. <article-title>A clinicopathologic analysis of atypical proliferative (borderline) tumors and well-differentiated endometrioid adenocarcinomas of the ovary</article-title>. <source>Am J Surg Pathol</source>. <volume>24</volume>:<fpage>1465</fpage>–<lpage>1479</lpage>.</citation>
</ref>
<ref id="bibr12-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bergamaschi</surname><given-names>A</given-names></name>
<name><surname>Kim</surname><given-names>YH</given-names></name>
<name><surname>Wang</surname><given-names>P</given-names></name>
<name><surname>Sorlie</surname><given-names>T</given-names></name>
<name><surname>Hernandez-Boussard</surname><given-names>T</given-names></name>
<name><surname>Lonning</surname><given-names>PE</given-names></name>
<name><surname>Tibshirani</surname><given-names>R</given-names></name>
<name><surname>Borresen-Dale</surname><given-names>AL</given-names></name>
<name><surname>Pollack</surname><given-names>JR</given-names></name>
</person-group>. <year>2006</year>. <article-title>Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer</article-title>. <source>Genes Chromosomes Cancer</source>. <volume>45</volume>:<fpage>1033</fpage>–<lpage>1040</lpage>.</citation>
</ref>
<ref id="bibr13-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bharwani</surname><given-names>N</given-names></name>
<name><surname>Reznek</surname><given-names>RH</given-names></name>
<name><surname>Rockall</surname><given-names>AG</given-names></name>
</person-group>. <year>2011</year>. <article-title>Ovarian cancer management: the role of imaging and diagnostic challenges</article-title>. <source>Eur J Radiol</source>. <volume>78</volume>:<fpage>41</fpage>–<lpage>51</lpage>.</citation>
</ref>
<ref id="bibr14-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bhoola</surname><given-names>S</given-names></name>
<name><surname>Hoskins</surname><given-names>WJ</given-names></name>
</person-group>. <year>2006</year>. <article-title>Diagnosis and management of epithelial ovarian cancer</article-title>. <source>Obstet Gynecol</source>. <volume>107</volume>:<fpage>1399</fpage>–<lpage>1410</lpage>.</citation>
</ref>
<ref id="bibr15-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bild</surname><given-names>AH</given-names></name>
<name><surname>Yao</surname><given-names>G</given-names></name>
<name><surname>Chang</surname><given-names>JT</given-names></name>
<name><surname>Wang</surname><given-names>Q</given-names></name>
<name><surname>Potti</surname><given-names>A</given-names></name>
<name><surname>Chasse</surname><given-names>D</given-names></name>
<name><surname>Joshi</surname><given-names>MB</given-names></name>
<name><surname>Harpole</surname><given-names>D</given-names></name>
<name><surname>Lancaster</surname><given-names>JM</given-names></name>
<name><surname>Berchuck</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <year>2006</year>. <article-title>Oncogenic pathway signatures in human cancers as a guide to targeted therapies</article-title>. <source>Nature</source>. <volume>439</volume>:<fpage>353</fpage>–<lpage>357</lpage>.</citation>
</ref>
<ref id="bibr16-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bishop</surname><given-names>JR</given-names></name>
<name><surname>Schuksz</surname><given-names>M</given-names></name>
<name><surname>Esko</surname><given-names>JD</given-names></name>
</person-group>. <year>2007</year>. <article-title>Heparan sulphate proteoglycans fine-tune mammalian physiology</article-title>. <source>Nature</source>. <volume>446</volume>:<fpage>1030</fpage>–<lpage>1037</lpage>.</citation>
</ref>
<ref id="bibr17-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Capurro</surname><given-names>MI</given-names></name>
<name><surname>Xu</surname><given-names>P</given-names></name>
<name><surname>Shi</surname><given-names>W</given-names></name>
<name><surname>Li</surname><given-names>F</given-names></name>
<name><surname>Jia</surname><given-names>A</given-names></name>
<name><surname>Filmus</surname><given-names>J</given-names></name>
</person-group>. <year>2008</year>. <article-title>Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding</article-title>. <source>Dev Cell</source>. <volume>14</volume>:<fpage>700</fpage>–<lpage>711</lpage>.</citation>
</ref>
<ref id="bibr18-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chin</surname><given-names>K</given-names></name>
<name><surname>DeVries</surname><given-names>S</given-names></name>
<name><surname>Fridlyand</surname><given-names>J</given-names></name>
<name><surname>Spellman</surname><given-names>PT</given-names></name>
<name><surname>Roydasgupta</surname><given-names>R</given-names></name>
<name><surname>Kuo</surname><given-names>WL</given-names></name>
<name><surname>Lapuk</surname><given-names>A</given-names></name>
<name><surname>Neve</surname><given-names>RM</given-names></name>
<name><surname>Qian</surname><given-names>Z</given-names></name>
<name><surname>Ryder</surname><given-names>T</given-names></name><etal/>
</person-group>. <year>2006</year>. <article-title>Genomic and transcriptional aberrations linked to breast cancer pathophysiologies</article-title>. <source>Cancer Cell</source>. <volume>10</volume>:<fpage>529</fpage>–<lpage>541</lpage>.</citation>
</ref>
<ref id="bibr19-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Choi</surname><given-names>C</given-names></name>
<name><surname>Kim</surname><given-names>MH</given-names></name>
<name><surname>Juhng</surname><given-names>SW</given-names></name>
</person-group>. <year>1998</year>. <article-title>Loss of heterozygosity on chromosome XP22.2-p22.13 and Xq26.1-q27.1 in human breast carcinomas</article-title>. <source>J Korean Med Sci</source>. <volume>13</volume>:<fpage>311</fpage>–<lpage>316</lpage>.</citation>
</ref>
<ref id="bibr20-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Choi</surname><given-names>Y</given-names></name>
<name><surname>Kim</surname><given-names>H</given-names></name>
<name><surname>Chung</surname><given-names>H</given-names></name>
<name><surname>Hwang</surname><given-names>JS</given-names></name>
<name><surname>Shin</surname><given-names>JA</given-names></name>
<name><surname>Oh</surname><given-names>ES</given-names></name>
</person-group>. <year>2010</year>. <article-title>Syndecan-2 regulates cell migration in colon cancer cells through Tiam1-mediated Rac activation</article-title>. <source>Biochem Biophys Res Commun</source>. <volume>391</volume>:<fpage>921</fpage>–<lpage>925</lpage>.</citation>
</ref>
<ref id="bibr21-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Christie</surname><given-names>M</given-names></name>
<name><surname>Oehler</surname><given-names>MK</given-names></name>
</person-group>. <year>2006</year>. <article-title>Molecular pathology of epithelial ovarian cancer</article-title>. <source>J Br Menopause Soc</source>. <volume>12</volume>:<fpage>57</fpage>–<lpage>63</lpage>.</citation>
</ref>
<ref id="bibr22-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Couchman</surname><given-names>JR</given-names></name>
</person-group>. <year>2003</year>. <article-title>Syndecans: proteoglycan regulators of cell-surface microdomains?</article-title> <source>Nat Rev Mol Cell Biol</source>. <volume>4</volume>:<fpage>926</fpage>–<lpage>937</lpage>.</citation>
</ref>
<ref id="bibr23-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Couchman</surname><given-names>JR</given-names></name>
</person-group>. <year>2010</year>. <article-title>Transmembrane signaling proteoglycans</article-title>. <source>Annu Rev Cell Dev Biol</source>. <volume>26</volume>:<fpage>89</fpage>–<lpage>114</lpage>.</citation>
</ref>
<ref id="bibr24-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Daly</surname><given-names>M</given-names></name>
<name><surname>Obrams</surname><given-names>GI</given-names></name>
</person-group>. <year>1998</year>. <article-title>Epidemiology and risk assessment for ovarian cancer</article-title>. <source>Semin Oncol</source>. <volume>25</volume>:<fpage>255</fpage>–<lpage>264</lpage>.</citation>
</ref>
<ref id="bibr25-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Davies</surname><given-names>EJ</given-names></name>
<name><surname>Blackhall</surname><given-names>FH</given-names></name>
<name><surname>Shanks</surname><given-names>JH</given-names></name>
<name><surname>David</surname><given-names>G</given-names></name>
<name><surname>McGown</surname><given-names>AT</given-names></name>
<name><surname>Swindell</surname><given-names>R</given-names></name>
<name><surname>Slade</surname><given-names>RJ</given-names></name>
<name><surname>Martin-Hirsch</surname><given-names>P</given-names></name>
<name><surname>Gallagher</surname><given-names>JT</given-names></name>
<name><surname>Jayson</surname><given-names>GC</given-names></name>
</person-group>. <year>2004</year>. <article-title>Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer</article-title>. <source>Clin Cancer Res</source>. <volume>10</volume>:<fpage>5178</fpage>–<lpage>5186</lpage>.</citation>
</ref>
<ref id="bibr26-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Cat</surname><given-names>B</given-names></name>
<name><surname>Muyldermans</surname><given-names>SY</given-names></name>
<name><surname>Coomans</surname><given-names>C</given-names></name>
<name><surname>Degeest</surname><given-names>G</given-names></name>
<name><surname>Vanderschueren</surname><given-names>B</given-names></name>
<name><surname>Creemers</surname><given-names>J</given-names></name>
<name><surname>Biemar</surname><given-names>F</given-names></name>
<name><surname>Peers</surname><given-names>B</given-names></name>
<name><surname>David</surname><given-names>G</given-names></name>
</person-group>. <year>2003</year>. <article-title>Processing by proprotein convertases is required for glypican-3 modulation of cell survival, Wnt signaling, and gastrulation movements</article-title>. <source>J Cell Biol</source>. <volume>163</volume>:<fpage>625</fpage>–<lpage>635</lpage>.</citation>
</ref>
<ref id="bibr27-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dews</surname><given-names>IC</given-names></name>
<name><surname>Mackenzie</surname><given-names>KR</given-names></name>
</person-group>. <year>2007</year>. <article-title>Transmembrane domains of the syndecan family of growth factor coreceptors display a hierarchy of homotypic and heterotypic interactions</article-title>. <source>Proc Natl Acad Sci U S A</source>. <volume>104</volume>:<fpage>20782</fpage>–<lpage>20787</lpage>.</citation>
</ref>
<ref id="bibr28-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ding</surname><given-names>K</given-names></name>
<name><surname>Lopez-Burks</surname><given-names>M</given-names></name>
<name><surname>Sanchez-Duran</surname><given-names>JA</given-names></name>
<name><surname>Korc</surname><given-names>M</given-names></name>
<name><surname>Lander</surname><given-names>AD</given-names></name>
</person-group>. <year>2005</year>. <article-title>Growth factor–induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells</article-title>. <source>J Cell Biol</source>. <volume>171</volume>:<fpage>729</fpage>–<lpage>738</lpage>.</citation>
</ref>
<ref id="bibr29-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dubash</surname><given-names>AD</given-names></name>
<name><surname>Menold</surname><given-names>MM</given-names></name>
<name><surname>Samson</surname><given-names>T</given-names></name>
<name><surname>Boulter</surname><given-names>E</given-names></name>
<name><surname>Garcia-Mata</surname><given-names>R</given-names></name>
<name><surname>Doughman</surname><given-names>R</given-names></name>
<name><surname>Burridge</surname><given-names>K</given-names></name>
</person-group>. <year>2009</year>. <article-title>Focal adhesions: new angles on an old structure</article-title>. <source>Int Rev Cell Mol Biol</source>. <volume>277</volume>:<fpage>1</fpage>–<lpage>65</lpage>.</citation>
</ref>
<ref id="bibr30-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dumitrescu</surname><given-names>RG</given-names></name>
<name><surname>Shields</surname><given-names>PG</given-names></name>
</person-group>. <year>2005</year>. <article-title>The etiology of alcohol-induced breast cancer</article-title>. <source>Alcohol</source>. <volume>35</volume>:<fpage>213</fpage>–<lpage>225</lpage>.</citation>
</ref>
<ref id="bibr31-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Echtermeyer</surname><given-names>F</given-names></name>
<name><surname>Streit</surname><given-names>M</given-names></name>
<name><surname>Wilcox-Adelman</surname><given-names>S</given-names></name>
<name><surname>Saoncella</surname><given-names>S</given-names></name>
<name><surname>Denhez</surname><given-names>F</given-names></name>
<name><surname>Detmar</surname><given-names>M</given-names></name>
<name><surname>Goetinck</surname><given-names>P</given-names></name>
</person-group>. <year>2001</year>. <article-title>Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4</article-title>. <source>J Clin Invest</source>. <volume>107</volume>:<fpage>R9</fpage>–<lpage>R14</lpage>.</citation>
</ref>
<ref id="bibr32-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Esheba</surname><given-names>GE</given-names></name>
<name><surname>Pate</surname><given-names>LL</given-names></name>
<name><surname>Longacre</surname><given-names>TA</given-names></name>
</person-group>. <year>2008</year>. <article-title>Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary</article-title>. <source>Am J Surg Pathol</source>. <volume>32</volume>:<fpage>600</fpage>–<lpage>607</lpage>.</citation>
</ref>
<ref id="bibr33-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Esko</surname><given-names>JD</given-names></name>
<name><surname>Selleck</surname><given-names>SB</given-names></name>
</person-group>. <year>2002</year>. <article-title>Order out of chaos: assembly of ligand binding sites in heparan sulfate</article-title>. <source>Annu Rev Biochem</source>. <volume>71</volume>:<fpage>435</fpage>–<lpage>471</lpage>.</citation>
</ref>
<ref id="bibr34-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fears</surname><given-names>CY</given-names></name>
<name><surname>Gladson</surname><given-names>CL</given-names></name>
<name><surname>Woods</surname><given-names>A</given-names></name>
</person-group>. <year>2006</year>. <article-title>Syndecan-2 is expressed in the microvasculature of gliomas and regulates angiogenic processes in microvascular endothelial cells</article-title>. <source>J Biol Chem</source>. <volume>281</volume>:<fpage>14533</fpage>–<lpage>14536</lpage>.</citation>
</ref>
<ref id="bibr35-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Filmus</surname><given-names>J</given-names></name>
<name><surname>Capurro</surname><given-names>M</given-names></name>
<name><surname>Rast</surname><given-names>J</given-names></name>
</person-group>. <year>2008</year>. <article-title>Glypicans</article-title>. <source>Genome Biol</source>. <volume>9</volume>:<fpage>224</fpage>.</citation>
</ref>
<ref id="bibr36-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fujiya</surname><given-names>M</given-names></name>
<name><surname>Watari</surname><given-names>J</given-names></name>
<name><surname>Ashida</surname><given-names>T</given-names></name>
<name><surname>Honda</surname><given-names>M</given-names></name>
<name><surname>Tanabe</surname><given-names>H</given-names></name>
<name><surname>Fujiki</surname><given-names>T</given-names></name>
<name><surname>Saitoh</surname><given-names>Y</given-names></name>
<name><surname>Kohgo</surname><given-names>Y</given-names></name>
</person-group>. <year>2001</year>. <article-title>Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer</article-title>. <source>Jpn J Cancer Res</source>. <volume>92</volume>:<fpage>1074</fpage>–<lpage>1081</lpage>.</citation>
</ref>
<ref id="bibr37-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fuster</surname><given-names>MM</given-names></name>
<name><surname>Esko</surname><given-names>JD</given-names></name>
</person-group>. <year>2005</year>. <article-title>The sweet and sour of cancer: glycans as novel therapeutic targets</article-title>. <source>Nat Rev Cancer</source>. <volume>5</volume>:<fpage>526</fpage>–<lpage>542</lpage>.</citation>
</ref>
<ref id="bibr38-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gemignani</surname><given-names>ML</given-names></name>
<name><surname>Schlaerth</surname><given-names>AC</given-names></name>
<name><surname>Bogomolniy</surname><given-names>F</given-names></name>
<name><surname>Barakat</surname><given-names>RR</given-names></name>
<name><surname>Lin</surname><given-names>O</given-names></name>
<name><surname>Soslow</surname><given-names>R</given-names></name>
<name><surname>Venkatraman</surname><given-names>E</given-names></name>
<name><surname>Boyd</surname><given-names>J</given-names></name>
</person-group>. <year>2003</year>. <article-title>Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma</article-title>. <source>Gynecol Oncol</source>. <volume>90</volume>:<fpage>378</fpage>–<lpage>381</lpage>.</citation>
</ref>
<ref id="bibr39-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gonzalez</surname><given-names>AD</given-names></name>
<name><surname>Kaya</surname><given-names>M</given-names></name>
<name><surname>Shi</surname><given-names>W</given-names></name>
<name><surname>Song</surname><given-names>H</given-names></name>
<name><surname>Testa</surname><given-names>JR</given-names></name>
<name><surname>Penn</surname><given-names>LZ</given-names></name>
<name><surname>Filmus</surname><given-names>J</given-names></name>
</person-group>. <year>1998</year>. <article-title>OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line–specific manner</article-title>. <source>J Cell Biol</source>. <volume>141</volume>:<fpage>1407</fpage>–<lpage>1414</lpage>.</citation>
</ref>
<ref id="bibr40-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Harvey</surname><given-names>JM</given-names></name>
<name><surname>Clark</surname><given-names>GM</given-names></name>
<name><surname>Osborne</surname><given-names>CK</given-names></name>
<name><surname>Allred</surname><given-names>DC</given-names></name>
</person-group>. <year>1999</year>. <article-title>Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer</article-title>. <source>J Clin Oncol</source>. <volume>17</volume>:<fpage>1474</fpage>–<lpage>1481</lpage>.</citation>
</ref>
<ref id="bibr41-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hennessy</surname><given-names>BT</given-names></name>
<name><surname>Coleman</surname><given-names>RL</given-names></name>
<name><surname>Markman</surname><given-names>M</given-names></name>
</person-group>. <year>2009</year>. <article-title>Ovarian cancer</article-title>. <source>Lancet</source>. <volume>374</volume>:<fpage>1371</fpage>–<lpage>1382</lpage>.</citation>
</ref>
<ref id="bibr42-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Iozzo</surname><given-names>RV</given-names></name>
<name><surname>Zoeller</surname><given-names>JJ</given-names></name>
<name><surname>Nyström</surname><given-names>A</given-names></name>
</person-group>. <year>2009</year>. <article-title>Basement membrane proteoglycans: modulators par excellence of cancer growth and metastasis</article-title>. <source>Mol Cells</source>. <volume>27</volume>:<fpage>503</fpage>–<lpage>513</lpage>.</citation>
</ref>
<ref id="bibr43-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jemal</surname><given-names>A</given-names></name>
<name><surname>Siegel</surname><given-names>R</given-names></name>
<name><surname>Ward</surname><given-names>E</given-names></name>
<name><surname>Hao</surname><given-names>Y</given-names></name>
<name><surname>Xu</surname><given-names>J</given-names></name>
<name><surname>Thun</surname><given-names>MJ</given-names></name>
</person-group>. <year>2009</year>. <article-title>Cancer statistics, 2009</article-title>. <source>CA Cancer J Clin</source>. <volume>59</volume>:<fpage>225</fpage>–<lpage>249</lpage>.</citation>
</ref>
<ref id="bibr44-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kamangar</surname><given-names>F</given-names></name>
<name><surname>Dores</surname><given-names>GM</given-names></name>
<name><surname>Anderson</surname><given-names>WF</given-names></name>
</person-group>. <year>2006</year>. <article-title>Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world</article-title>. <source>J Clin Oncol</source>. <volume>24</volume>:<fpage>2137</fpage>–<lpage>2150</lpage>.</citation>
</ref>
<ref id="bibr45-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Karamanos</surname><given-names>NK</given-names></name>
<name><surname>Vanky</surname><given-names>P</given-names></name>
<name><surname>Tzanakakis</surname><given-names>GN</given-names></name>
<name><surname>Hjerpe</surname><given-names>A</given-names></name>
</person-group>. <year>1996</year>. <article-title>High performance capillary electrophoresis method to characterize heparin and heparan sulfate disaccharides</article-title>. <source>Electrophoresis</source>. <volume>17</volume>:<fpage>391</fpage>–<lpage>395</lpage>.</citation>
</ref>
<ref id="bibr46-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Keum</surname><given-names>E</given-names></name>
<name><surname>Kim</surname><given-names>Y</given-names></name>
<name><surname>Kim</surname><given-names>J</given-names></name>
<name><surname>Kwon</surname><given-names>S</given-names></name>
<name><surname>Lim</surname><given-names>Y</given-names></name>
<name><surname>Han</surname><given-names>I</given-names></name>
<name><surname>Oh</surname><given-names>ES</given-names></name>
</person-group>. <year>2004</year>. <article-title>Syndecan-4 regulates localization, activity and stability of protein kinase Cα</article-title>. <source>Biochem J</source>. <volume>378</volume>:<fpage>1007</fpage>–<lpage>1014</lpage>.</citation>
</ref>
<ref id="bibr47-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>H</given-names></name>
<name><surname>Wu</surname><given-names>R</given-names></name>
<name><surname>Cho</surname><given-names>KR</given-names></name>
<name><surname>Thomas</surname><given-names>DG</given-names></name>
<name><surname>Gossner</surname><given-names>G</given-names></name>
<name><surname>Liu</surname><given-names>JR</given-names></name>
<name><surname>Giordano</surname><given-names>TJ</given-names></name>
<name><surname>Shedden</surname><given-names>KA</given-names></name>
<name><surname>Misek</surname><given-names>DE</given-names></name>
<name><surname>Lubman</surname><given-names>DM</given-names></name>
</person-group>. <year>2008</year>. <article-title>Comparative proteomic analysis of low stage and high stage endometrioid ovarian adenocarcinomas</article-title>. <source>Proteomics Clin Appl</source>. <volume>2</volume>:<fpage>571</fpage>–<lpage>584</lpage>.</citation>
</ref>
<ref id="bibr48-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kirkpatrick</surname><given-names>CA</given-names></name>
<name><surname>Selleck</surname><given-names>SB</given-names></name>
</person-group>. <year>2007</year>. <article-title>Heparan sulfate proteoglycans at a glance</article-title>. <source>J Cell Sci</source>. <volume>120</volume>:<fpage>1829</fpage>–<lpage>1832</lpage>.</citation>
</ref>
<ref id="bibr49-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kousidou</surname><given-names>OC</given-names></name>
<name><surname>Berdiaki</surname><given-names>A</given-names></name>
<name><surname>Kletsas</surname><given-names>D</given-names></name>
<name><surname>Zafiropoulos</surname><given-names>A</given-names></name>
<name><surname>Theiocharis</surname><given-names>AD</given-names></name>
<name><surname>Tzanakakis</surname><given-names>GN</given-names></name>
<name><surname>Karamanos</surname><given-names>NK</given-names></name>
</person-group>. <year>2008</year>. <article-title>Estradiol-estrogen receptor: a key interplay of the expression of syndecan-2 and metalloproteinase-9 in breast cancer cells</article-title>. <source>Mol Oncol</source>. <volume>2</volume>:<fpage>223</fpage>–<lpage>232</lpage>.</citation>
</ref>
<ref id="bibr50-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kreuger</surname><given-names>J</given-names></name>
<name><surname>Perez</surname><given-names>L</given-names></name>
<name><surname>Giraldez</surname><given-names>AJ</given-names></name>
<name><surname>Cohen</surname><given-names>SM</given-names></name>
</person-group>. <year>2004</year>. <article-title>Opposing activities of Dally-like glypican at high and low levels of Wingless morphogen activity</article-title>. <source>Dev Cell</source>. <volume>7</volume>:<fpage>503</fpage>–<lpage>512</lpage>.</citation>
</ref>
<ref id="bibr51-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kreuger</surname><given-names>J</given-names></name>
<name><surname>Spillmann</surname><given-names>D</given-names></name>
<name><surname>Li</surname><given-names>JP</given-names></name>
<name><surname>Lindahl</surname><given-names>U</given-names></name>
</person-group>. <year>2006</year>. <article-title>Interactions between heparan sulfate and proteins: the concept of specificity</article-title>. <source>J Cell Biol</source>. <volume>174</volume>:<fpage>323</fpage>–<lpage>327</lpage>.</citation>
</ref>
<ref id="bibr52-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kurman</surname><given-names>RJ</given-names></name>
<name><surname>Visvanathan</surname><given-names>K</given-names></name>
<name><surname>Roden</surname><given-names>R</given-names></name>
<name><surname>Wu</surname><given-names>TC</given-names></name>
<name><surname>Shih</surname><given-names>IM</given-names></name>
</person-group>. <year>2008</year>. <article-title>Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis</article-title>. <source>Am J Obstet Gynecol</source>. <volume>198</volume>:<fpage>351</fpage>–<lpage>356</lpage>.</citation>
</ref>
<ref id="bibr53-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>La</surname><given-names>VC</given-names></name>
<name><surname>Bosetti</surname><given-names>C</given-names></name>
<name><surname>Lucchini</surname><given-names>F</given-names></name>
<name><surname>Bertuccio</surname><given-names>P</given-names></name>
<name><surname>Negri</surname><given-names>E</given-names></name>
<name><surname>Boyle</surname><given-names>P</given-names></name>
<name><surname>Levi</surname><given-names>F</given-names></name>
</person-group>. <year>2010</year>. <article-title>Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975</article-title>. <source>Ann Oncol</source>. <volume>21</volume>:<fpage>1323</fpage>–<lpage>1360</lpage>.</citation>
</ref>
<ref id="bibr54-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>D</given-names></name>
<name><surname>Oh</surname><given-names>ES</given-names></name>
<name><surname>Woods</surname><given-names>A</given-names></name>
<name><surname>Couchman</surname><given-names>JR</given-names></name>
<name><surname>Lee</surname><given-names>W</given-names></name>
</person-group>. <year>1998</year>. <article-title>Solution structure of a syndecan-4 cytoplasmic domain and its interaction with phosphatidylinositol 4,5 bisphosphate</article-title>. <source>J Biol Chem</source>. <volume>273</volume>:<fpage>13022</fpage>–<lpage>13029</lpage>.</citation>
</ref>
<ref id="bibr55-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lendorf</surname><given-names>ME</given-names></name>
<name><surname>Manon-Jensen</surname><given-names>T</given-names></name>
<name><surname>Kronqvist</surname><given-names>P</given-names></name>
<name><surname>Multhaupt</surname><given-names>HA</given-names></name>
<name><surname>Couchman</surname><given-names>JR</given-names></name>
</person-group>. <year>2011</year>. <article-title>Syndecan-1 and syndecan-4 are independent indicators in breast carcinoma</article-title>. <source>J Histochem Cytochem</source>. <volume>59</volume>:<fpage>615</fpage>–<lpage>629</lpage>.</citation>
</ref>
<ref id="bibr56-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>CI</given-names></name>
<name><surname>Malone</surname><given-names>KE</given-names></name>
<name><surname>Porter</surname><given-names>PL</given-names></name>
<name><surname>Weiss</surname><given-names>NS</given-names></name>
<name><surname>Tang</surname><given-names>MT</given-names></name>
<name><surname>Cushing-Haugen</surname><given-names>KL</given-names></name>
<name><surname>Daling</surname><given-names>JR</given-names></name>
</person-group>. <year>2003</year>. <article-title>Relationship between long durations and different regimens of hormone therapy and risk of breast cancer</article-title>. <source>JAMA</source>. <volume>289</volume>:<fpage>3254</fpage>–<lpage>3263</lpage>.</citation>
</ref>
<ref id="bibr57-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lin</surname><given-names>H</given-names></name>
<name><surname>Huber</surname><given-names>R</given-names></name>
<name><surname>Schlessinger</surname><given-names>D</given-names></name>
<name><surname>Morin</surname><given-names>PJ</given-names></name>
</person-group>. <year>1999</year>. <article-title>Frequent silencing of the GPC3 gene in ovarian cancer cell lines</article-title>. <source>Cancer Res</source>. <volume>59</volume>:<fpage>807</fpage>–<lpage>810</lpage>.</citation>
</ref>
<ref id="bibr58-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lin</surname><given-names>X</given-names></name>
</person-group>. <year>2004</year>. <article-title>Functions of heparan sulfate proteoglycans in cell signaling during development</article-title>. <source>Development</source>. <volume>131</volume>:<fpage>6009</fpage>–<lpage>6021</lpage>.</citation>
</ref>
<ref id="bibr59-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lindahl</surname><given-names>U</given-names></name>
<name><surname>Li</surname><given-names>JP</given-names></name>
</person-group>. <year>2009</year>. <article-title>Interactions between heparan sulfate and proteins: design and functional implications</article-title>. <source>Int Rev Cell Mol Biol</source>. <volume>276</volume>:<fpage>105</fpage>–<lpage>159</lpage>.</citation>
</ref>
<ref id="bibr60-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Longley</surname><given-names>RL</given-names></name>
<name><surname>Woods</surname><given-names>A</given-names></name>
<name><surname>Fleetwood</surname><given-names>A</given-names></name>
<name><surname>Cowling</surname><given-names>GJ</given-names></name>
<name><surname>Gallagher</surname><given-names>JT</given-names></name>
<name><surname>Couchman</surname><given-names>JR</given-names></name>
</person-group>. <year>1999</year>. <article-title>Control of morphology, cytoskeleton and migration by syndecan-4</article-title>. <source>J Cell Sci</source>. <volume>112</volume>:<fpage>3421</fpage>–<lpage>3431</lpage>.</citation>
</ref>
<ref id="bibr61-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lundin</surname><given-names>M</given-names></name>
<name><surname>Nordling</surname><given-names>S</given-names></name>
<name><surname>Lundin</surname><given-names>J</given-names></name>
<name><surname>Isola</surname><given-names>J</given-names></name>
<name><surname>Wiksten</surname><given-names>JP</given-names></name>
<name><surname>Haglund</surname><given-names>C</given-names></name>
</person-group>. <year>2005</year>. <article-title>Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer</article-title>. <source>Oncology</source>. <volume>68</volume>:<fpage>306</fpage>–<lpage>313</lpage>.</citation>
</ref>
<ref id="bibr62-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Maeda</surname><given-names>D</given-names></name>
<name><surname>Ota</surname><given-names>S</given-names></name>
<name><surname>Takazawa</surname><given-names>Y</given-names></name>
<name><surname>Aburatani</surname><given-names>H</given-names></name>
<name><surname>Nakagawa</surname><given-names>S</given-names></name>
<name><surname>Yano</surname><given-names>T</given-names></name>
<name><surname>Taketani</surname><given-names>Y</given-names></name>
<name><surname>Kodama</surname><given-names>T</given-names></name>
<name><surname>Fukayama</surname><given-names>M</given-names></name>
</person-group>. <year>2009</year>. <article-title>Glypican-3 expression in clear cell adenocarcinoma of the ovary</article-title>. <source>Mod Pathol</source>. <volume>22</volume>:<fpage>824</fpage>–<lpage>832</lpage>.</citation>
</ref>
<ref id="bibr63-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Manon-Jensen</surname><given-names>T</given-names></name>
<name><surname>Itoh</surname><given-names>Y</given-names></name>
<name><surname>Couchman</surname><given-names>JR</given-names></name>
</person-group>. <year>2010</year>. <article-title>Proteoglycans in health and disease: the multiple roles of syndecan shedding</article-title>. <source>FEBS J</source>. <volume>277</volume>:<fpage>3876</fpage>–<lpage>3889</lpage>.</citation>
</ref>
<ref id="bibr64-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Matsuda</surname><given-names>K</given-names></name>
<name><surname>Maruyama</surname><given-names>H</given-names></name>
<name><surname>Guo</surname><given-names>F</given-names></name>
<name><surname>Kleeff</surname><given-names>J</given-names></name>
<name><surname>Itakura</surname><given-names>J</given-names></name>
<name><surname>Matsumoto</surname><given-names>Y</given-names></name>
<name><surname>Lander</surname><given-names>AD</given-names></name>
<name><surname>Korc</surname><given-names>M</given-names></name>
</person-group>. <year>2001</year>. <article-title>Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells</article-title>. <source>Cancer Res</source>. <volume>61</volume>:<fpage>5562</fpage>–<lpage>5569</lpage>.</citation>
</ref>
<ref id="bibr65-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Modrowski</surname><given-names>D</given-names></name>
<name><surname>Orosco</surname><given-names>A</given-names></name>
<name><surname>Thévenard</surname><given-names>J</given-names></name>
<name><surname>Fromigué</surname><given-names>O</given-names></name>
<name><surname>Marie</surname><given-names>PJ</given-names></name>
</person-group>. <year>2005</year>. <article-title>Syndecan-2 overexpression induces osteosarcoma cell apoptosis: implication of syndecan-2 cytoplasmic domain and JNK signaling</article-title>. <source>Bone</source>. <volume>37</volume>:<fpage>180</fpage>–<lpage>189</lpage>.</citation>
</ref>
<ref id="bibr66-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mohsin</surname><given-names>SK</given-names></name>
<name><surname>Weiss</surname><given-names>H</given-names></name>
<name><surname>Havighurst</surname><given-names>T</given-names></name>
<name><surname>Clark</surname><given-names>GM</given-names></name>
<name><surname>Berardo</surname><given-names>M</given-names></name>
<name><surname>Roanh</surname><given-names>lD</given-names></name>
<name><surname>To</surname><given-names>TV</given-names></name>
<name><surname>Qian</surname><given-names>Z</given-names></name>
<name><surname>Love</surname><given-names>RR</given-names></name>
<name><surname>Allred</surname><given-names>DC</given-names></name>
</person-group>. <year>2004</year>. <article-title>Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study</article-title>. <source>Mod Pathol</source>. <volume>17</volume>:<fpage>1545</fpage>–<lpage>1554</lpage>.</citation>
</ref>
<ref id="bibr67-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morgan</surname><given-names>MR</given-names></name>
<name><surname>Humphries</surname><given-names>MJ</given-names></name>
<name><surname>Bass</surname><given-names>MD</given-names></name>
</person-group>. <year>2007</year>. <article-title>Synergistic control of cell adhesion by integrins and syndecans</article-title>. <source>Nat Rev Mol Cell Biol</source>. <volume>8</volume>:<fpage>957</fpage>–<lpage>969</lpage>.</citation>
</ref>
<ref id="bibr68-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morimoto-Tomita</surname><given-names>M</given-names></name>
<name><surname>Uchimura</surname><given-names>K</given-names></name>
<name><surname>Bistrup</surname><given-names>A</given-names></name>
<name><surname>Lum</surname><given-names>DH</given-names></name>
<name><surname>Egeblad</surname><given-names>M</given-names></name>
<name><surname>Boudreau</surname><given-names>N</given-names></name>
<name><surname>Werb</surname><given-names>Z</given-names></name>
<name><surname>Rosen</surname><given-names>SD</given-names></name>
</person-group>. <year>2005</year>. <article-title>Sulf-2, a proangiogenic heparan sulfate endosulfatase, is upregulated in breast cancer</article-title>. <source>Neoplasia</source>. <volume>7</volume>:<fpage>1001</fpage>–<lpage>1010</lpage>.</citation>
</ref>
<ref id="bibr69-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mullan</surname><given-names>PB</given-names></name>
<name><surname>Millikan</surname><given-names>RC</given-names></name>
</person-group>. <year>2007</year>. <article-title>Molecular subtyping of breast cancer: opportunities for new therapeutic approaches</article-title>. <source>Cell Mol Life Sci</source>. <volume>64</volume>:<fpage>3219</fpage>–<lpage>3232</lpage>.</citation>
</ref>
<ref id="bibr70-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Multhaupt</surname><given-names>HA</given-names></name>
<name><surname>Yoneda</surname><given-names>A</given-names></name>
<name><surname>Whiteford</surname><given-names>JR</given-names></name>
<name><surname>Oh</surname><given-names>ES</given-names></name>
<name><surname>Lee</surname><given-names>W</given-names></name>
<name><surname>Couchman</surname><given-names>JR</given-names></name>
</person-group>. <year>2009</year>. <article-title>Syndecan signaling: when, where and why?</article-title> <source>J Physiol Pharmacol</source>. <volume>60</volume>(<issue>Suppl 4</issue>):<fpage>31</fpage>–<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr71-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mundhenke</surname><given-names>C</given-names></name>
<name><surname>Meyer</surname><given-names>K</given-names></name>
<name><surname>Drew</surname><given-names>S</given-names></name>
<name><surname>Friedl</surname><given-names>A</given-names></name>
</person-group>. <year>2002</year>. <article-title>Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas</article-title>. <source>Am J Pathol</source>. <volume>160</volume>:<fpage>185</fpage>–<lpage>194</lpage>.</citation>
</ref>
<ref id="bibr72-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Murphy</surname><given-names>KJ</given-names></name>
<name><surname>Merry</surname><given-names>CL</given-names></name>
<name><surname>Lyon</surname><given-names>M</given-names></name>
<name><surname>Thompson</surname><given-names>JE</given-names></name>
<name><surname>Roberts</surname><given-names>IS</given-names></name>
<name><surname>Gallagher</surname><given-names>JT</given-names></name>
</person-group>. <year>2004</year>. <article-title>A new model for the domain structure of heparan sulfate based on the novel specificity of K5 lyase</article-title>. <source>J Biol Chem</source>. <volume>279</volume>:<fpage>27239</fpage>–<lpage>27245</lpage>.</citation>
</ref>
<ref id="bibr73-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mythreye</surname><given-names>K</given-names></name>
<name><surname>Blobe</surname><given-names>GC</given-names></name>
</person-group>. <year>2009</year>. <article-title>Proteoglycan signaling co-receptors: roles in cell adhesion, migration and invasion</article-title>. <source>Cell Signal</source>. <volume>21</volume>:<fpage>1548</fpage>–<lpage>1558</lpage>.</citation>
</ref>
<ref id="bibr74-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Park</surname><given-names>H</given-names></name>
<name><surname>Kim</surname><given-names>Y</given-names></name>
<name><surname>Lim</surname><given-names>Y</given-names></name>
<name><surname>Han</surname><given-names>I</given-names></name>
<name><surname>Oh</surname><given-names>ES</given-names></name>
</person-group>. <year>2002</year>. <article-title>Syndecan-2 mediates adhesion and proliferation of colon carcinoma cells</article-title>. <source>J Biol Chem</source>. <volume>277</volume>:<fpage>29730</fpage>–<lpage>29736</lpage>.</citation>
</ref>
<ref id="bibr75-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Payne</surname><given-names>SJ</given-names></name>
<name><surname>Bowen</surname><given-names>RL</given-names></name>
<name><surname>Jones</surname><given-names>JL</given-names></name>
<name><surname>Wells</surname><given-names>CA</given-names></name>
</person-group>. <year>2008</year>. <article-title>Predictive markers in breast cancer—the present</article-title>. <source>Histopathology</source>. <volume>52</volume>:<fpage>82</fpage>–<lpage>90</lpage>.</citation>
</ref>
<ref id="bibr76-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Perou</surname><given-names>CM</given-names></name>
<name><surname>Sørlie</surname><given-names>T</given-names></name>
<name><surname>Eisen</surname><given-names>MB</given-names></name>
<name><surname>van</surname><given-names>de</given-names></name>
<name><surname>Rijn</surname><given-names>M</given-names></name>
<name><surname>Jeffrey</surname><given-names>SS</given-names></name>
<name><surname>Rees</surname><given-names>CA</given-names></name>
<name><surname>Pollack</surname><given-names>JR</given-names></name>
<name><surname>Ross</surname><given-names>DT</given-names></name>
<name><surname>Johnsen</surname><given-names>H</given-names></name>
<name><surname>Akslen</surname><given-names>LA</given-names></name>
<etal/>
</person-group>. <year>2000</year>. <article-title>Molecular portraits of human breast tumours</article-title>. <source>Nature</source>. <volume>406</volume>:<fpage>747</fpage>–<lpage>752</lpage>.</citation>
</ref>
<ref id="bibr77-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Peters</surname><given-names>MG</given-names></name>
<name><surname>Farias</surname><given-names>E</given-names></name>
<name><surname>Colombo</surname><given-names>L</given-names></name>
<name><surname>Filmus</surname><given-names>J</given-names></name>
<name><surname>Puricelli</surname><given-names>L</given-names></name>
<name><surname>Bal de Kier Joffe</surname><given-names>E</given-names></name>
</person-group>. <year>2003</year>. <article-title>Inhibition of invasion and metastasis by glypican-3 in a syngeneic breast cancer model</article-title>. <source>Breast Cancer Res Treat</source>. <volume>80</volume>:<fpage>221</fpage>–<lpage>232</lpage>.</citation>
</ref>
<ref id="bibr78-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pilia</surname><given-names>G</given-names></name>
<name><surname>Highes-Benzie</surname><given-names>RM</given-names></name>
<name><surname>MacKenzie</surname><given-names>A</given-names></name>
<name><surname>Baybayan</surname><given-names>P</given-names></name>
<name><surname>Chen</surname><given-names>EY</given-names></name>
<name><surname>Huber</surname><given-names>R</given-names></name>
<name><surname>Neri</surname><given-names>G</given-names></name>
<name><surname>Cao</surname><given-names>A</given-names></name>
<name><surname>Forabosco</surname><given-names>A</given-names></name>
<name><surname>Schlessinger</surname><given-names>D</given-names></name>
</person-group>. <year>1996</year>. <article-title>Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome</article-title>. <source>Nat Genet</source>. <volume>12</volume>:<fpage>241</fpage>–<lpage>247</lpage>.</citation>
</ref>
<ref id="bibr79-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ricciardelli</surname><given-names>C</given-names></name>
<name><surname>Rodgers</surname><given-names>RJ</given-names></name>
</person-group>. <year>2006</year>. <article-title>Extracellular matrix of ovarian tumors</article-title>. <source>Semin Reprod Med</source>. <volume>24</volume>:<fpage>270</fpage>–<lpage>282</lpage>.</citation>
</ref>
<ref id="bibr80-0022155411428469">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Rosen</surname><given-names>PP</given-names></name>
</person-group>. <year>2001</year>. <source>Rosen’s Breast Pathology</source>. <edition>2nd ed.</edition> <publisher-loc>Philadelphia</publisher-loc>: <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>.</citation>
</ref>
<ref id="bibr81-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rosen</surname><given-names>SD</given-names></name>
<name><surname>Lemjabbar-Alaoui</surname><given-names>H</given-names></name>
</person-group>. <year>2010</year>. <article-title>Sulf2: an extracellular modulator of cell signaling and a cancer target candidate</article-title>. <source>Expert Opin Ther Targets</source>. <volume>14</volume>:<fpage>935</fpage>–<lpage>949</lpage>.</citation>
</ref>
<ref id="bibr82-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ross</surname><given-names>JS</given-names></name>
<name><surname>Linette</surname><given-names>GP</given-names></name>
<name><surname>Stec</surname><given-names>J</given-names></name>
<name><surname>Clark</surname><given-names>E</given-names></name>
<name><surname>Ayers</surname><given-names>M</given-names></name>
<name><surname>Leschly</surname><given-names>N</given-names></name>
<name><surname>Symmans</surname><given-names>WF</given-names></name>
<name><surname>Hortobagyi</surname><given-names>GN</given-names></name>
<name><surname>Pusztai</surname><given-names>L</given-names></name>
</person-group>. <year>2004</year>. <article-title>Breast cancer biomarkers and molecular medicine: part II</article-title>. <source>Expert Rev Mol Diagn</source>. <volume>4</volume>:<fpage>169</fpage>–<lpage>188</lpage>.</citation>
</ref>
<ref id="bibr83-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ross</surname><given-names>JS</given-names></name>
<name><surname>Symmans</surname><given-names>WF</given-names></name>
<name><surname>Pusztai</surname><given-names>L</given-names></name>
<name><surname>Hortobagyi</surname><given-names>GN</given-names></name>
</person-group>. <year>2005</year>. <article-title>Breast cancer biomarkers</article-title>. <source>Adv Clin Chem</source>. <volume>40</volume>:<fpage>99</fpage>–<lpage>125</lpage>.</citation>
</ref>
<ref id="bibr84-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sainsbury</surname><given-names>JR</given-names></name>
<name><surname>Anderson</surname><given-names>TJ</given-names></name>
<name><surname>Morgan</surname><given-names>DA</given-names></name>
</person-group>. <year>2000</year>. <article-title>ABC of breast diseases: breast cancer</article-title>. <source>BMJ</source>. <volume>321</volume>:<fpage>745</fpage>–<lpage>750</lpage>.</citation>
</ref>
<ref id="bibr85-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sanderson</surname><given-names>RD</given-names></name>
<name><surname>Yang</surname><given-names>Y</given-names></name>
</person-group>. <year>2008</year>. <article-title>Syndecan-1: a dynamic regulator of the myeloma environment</article-title>. <source>Clin Exp Metastasis</source>. <volume>25</volume>:<fpage>149</fpage>–<lpage>159</lpage>.</citation>
</ref>
<ref id="bibr86-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schmeler</surname><given-names>KM</given-names></name>
<name><surname>Sun</surname><given-names>CC</given-names></name>
<name><surname>Bodurka</surname><given-names>DC</given-names></name>
<name><surname>White</surname><given-names>KG</given-names></name>
<name><surname>Soliman</surname><given-names>PT</given-names></name>
<name><surname>Uyei</surname><given-names>AR</given-names></name>
<name><surname>Erlichman</surname><given-names>JL</given-names></name>
<name><surname>Arun</surname><given-names>BK</given-names></name>
<name><surname>Daniels</surname><given-names>MS</given-names></name>
<name><surname>Rimes</surname><given-names>SA</given-names></name>
<etal/>
</person-group>. <year>2006</year>. <article-title>Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations</article-title>. <source>Obstet Gynecol</source>. <volume>108</volume>:<fpage>515</fpage>–<lpage>520</lpage>.</citation>
</ref>
<ref id="bibr87-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Seidman</surname><given-names>JD</given-names></name>
<name><surname>Kurman</surname><given-names>RJ</given-names></name>
</person-group>. <year>2003</year>. <article-title>Pathology of ovarian carcinoma</article-title>. <source>Hematol Oncol Clin North Am</source>. <volume>17</volume>:<fpage>909</fpage>–<lpage>925</lpage>.</citation>
</ref>
<ref id="bibr88-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shih</surname><given-names>IM</given-names></name>
<name><surname>Kurman</surname><given-names>RJ</given-names></name>
</person-group>. <year>2004</year>. <article-title>Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis</article-title>. <source>Am J Pathol</source>. <volume>164</volume>:<fpage>1511</fpage>–<lpage>1518</lpage>.</citation>
</ref>
<ref id="bibr89-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shinyo</surname><given-names>Y</given-names></name>
<name><surname>Kodama</surname><given-names>J</given-names></name>
<name><surname>Hasengaowa</surname></name>
<name><surname>Kusumoto</surname><given-names>T</given-names></name>
<name><surname>Hiramatsu</surname><given-names>Y</given-names></name>
</person-group>. <year>2005</year>. <article-title>Loss of cell-surface heparan sulfate expression in both cervical intraepithelial neoplasm and invasive cervical cancer</article-title>. <source>Gynecol Oncol</source>. <volume>96</volume>:<fpage>776</fpage>–<lpage>783</lpage>.</citation>
</ref>
<ref id="bibr90-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Singer</surname><given-names>G</given-names></name>
<name><surname>Oldt</surname><given-names>R</given-names><suffix>III</suffix></name>
<name><surname>Cohen</surname><given-names>Y</given-names></name>
<name><surname>Wang</surname><given-names>BG</given-names></name>
<name><surname>Sidransky</surname><given-names>D</given-names></name>
<name><surname>Kurman</surname><given-names>RJ</given-names></name>
<name><surname>Shih</surname><given-names>IM</given-names></name>
</person-group>. <year>2003</year>. <article-title>Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma</article-title>. <source>J Natl Cancer Inst</source>. <volume>95</volume>:<fpage>484</fpage>–<lpage>486</lpage>.</citation>
</ref>
<ref id="bibr91-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Skidmore</surname><given-names>MA</given-names></name>
<name><surname>Guimond</surname><given-names>SE</given-names></name>
<name><surname>Rudd</surname><given-names>TR</given-names></name>
<name><surname>Fernig</surname><given-names>DG</given-names></name>
<name><surname>Turnbull</surname><given-names>JE</given-names></name>
<name><surname>Yates</surname><given-names>EA</given-names></name>
</person-group>. <year>2008</year>. <article-title>The activities of heparan sulfate and its analogue heparin are dictated by biosynthesis, sequence and conformation</article-title>. <source>Conn Tiss Res</source>. <volume>49</volume>:<fpage>140</fpage>–<lpage>144</lpage>.</citation>
</ref>
<ref id="bibr92-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Song</surname><given-names>HH</given-names></name>
<name><surname>Shi</surname><given-names>W</given-names></name>
<name><surname>Filmus</surname><given-names>J</given-names></name>
</person-group>. <year>1997</year>. <article-title>OCI-5/rat glypican-3 binds to fibroblast growth factor-2 but not to insulin-like growth factor-2</article-title>. <source>J Biol Chem</source>. <volume>272</volume>:<fpage>7574</fpage>–<lpage>7577</lpage>.</citation>
</ref>
<ref id="bibr93-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Song</surname><given-names>HH</given-names></name>
<name><surname>Shi</surname><given-names>W</given-names></name>
<name><surname>Xiang</surname><given-names>YY</given-names></name>
<name><surname>Filmus</surname><given-names>J</given-names></name>
</person-group>. <year>2005</year>. <article-title>The loss of glypican-3 induces alterations in Wnt signaling</article-title>. <source>J Biol Chem</source>. <volume>280</volume>:<fpage>2116</fpage>–<lpage>2125</lpage>.</citation>
</ref>
<ref id="bibr94-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sorlie</surname><given-names>T</given-names></name>
<name><surname>Perou</surname><given-names>CM</given-names></name>
<name><surname>Tibshirani</surname><given-names>R</given-names></name>
<name><surname>Aas</surname><given-names>T</given-names></name>
<name><surname>Geisler</surname><given-names>S</given-names></name>
<name><surname>Johnsen</surname><given-names>H</given-names></name>
<name><surname>Hastie</surname><given-names>T</given-names></name>
<name><surname>Eisen</surname><given-names>MB</given-names></name>
<name><surname>Van de Rijn</surname><given-names>M</given-names></name>
<name><surname>Jeffrey</surname><given-names>SS</given-names></name>
<etal/>
</person-group>. <year>2001</year>. <article-title>Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications</article-title>. <source>Proc Natl Acad Sci U S A</source>. <volume>98</volume>:<fpage>10869</fpage>–<lpage>10874</lpage>.</citation>
</ref>
<ref id="bibr95-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stadlmann</surname><given-names>S</given-names></name>
<name><surname>Gueth</surname><given-names>U</given-names></name>
<name><surname>Baumhoer</surname><given-names>D</given-names></name>
<name><surname>Moch</surname><given-names>H</given-names></name>
<name><surname>Terracciano</surname><given-names>L</given-names></name>
<name><surname>Singer</surname><given-names>G</given-names></name>
</person-group>. <year>2007</year>. <article-title>Glypican-3 expression in primary and recurrent ovarian carcinomas</article-title>. <source>Int J Gynecol Pathol</source>. <volume>26</volume>:<fpage>341</fpage>–<lpage>344</lpage>.</citation>
</ref>
<ref id="bibr96-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Steigmann</surname><given-names>P</given-names></name>
<name><surname>Molitor</surname><given-names>A</given-names></name>
<name><surname>Fllert</surname><given-names>S</given-names></name>
<name><surname>Jäckle</surname><given-names>H</given-names></name>
<name><surname>Vorbrüggen</surname><given-names>G</given-names></name>
</person-group>. <year>2004</year>. <article-title>Heparan sulfate proteoglycan syndecan promotes axonal and myotube guidance by slit/robo signaling</article-title>. <source>Curr Biol</source>. <volume>14</volume>:<fpage>225</fpage>–<lpage>230</lpage>.</citation>
</ref>
<ref id="bibr97-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Subramaniam</surname><given-names>DS</given-names></name>
<name><surname>Isaacs</surname><given-names>C</given-names></name>
</person-group>. <year>2005</year>. <article-title>Utilizing prognostic and predictive factors in breast cancer</article-title>. <source>Curr Treat Options Oncol</source>. <volume>6</volume>:<fpage>147</fpage>–<lpage>159</lpage>.</citation>
</ref>
<ref id="bibr98-0022155411428469">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Tavassoli</surname><given-names>FA</given-names></name>
</person-group>. <year>1999</year>. <source>Pathology of the Breast</source>. <edition>2nd ed.</edition> <publisher-loc>Stamford, CT</publisher-loc>: <publisher-name>Appleton Lange</publisher-name>.</citation>
</ref>
<ref id="bibr99-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Theocharis</surname><given-names>AD</given-names></name>
<name><surname>Skandalis</surname><given-names>SS</given-names></name>
<name><surname>Tzanakakis</surname><given-names>GN</given-names></name>
<name><surname>Karamanos</surname><given-names>NK</given-names></name>
</person-group>. <year>2010</year>. <article-title>Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting</article-title>. <source>FEBS J</source>. <volume>277</volume>:<fpage>3904</fpage>–<lpage>3923</lpage>.</citation>
</ref>
<ref id="bibr100-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Umezu</surname><given-names>T</given-names></name>
<name><surname>Shibata</surname><given-names>K</given-names></name>
<name><surname>Kajiyama</surname><given-names>H</given-names></name>
<name><surname>Yamamoto</surname><given-names>E</given-names></name>
<name><surname>Nawa</surname><given-names>A</given-names></name>
<name><surname>Kikkawa</surname><given-names>F</given-names></name>
</person-group>. <year>2010</year>. <article-title>Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary</article-title>. <source>J Clin Pathol</source>. <volume>63</volume>:<fpage>962</fpage>–<lpage>966</lpage>.</citation>
</ref>
<ref id="bibr101-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vargo-Gogola</surname><given-names>T</given-names></name>
<name><surname>Rosen</surname><given-names>JM</given-names></name>
</person-group>. <year>2007</year>. <article-title>Modelling breast cancer: one size does not fit all</article-title>. <source>Nat Rev Cancer</source>. <volume>7</volume>:<fpage>659</fpage>–<lpage>672</lpage>.</citation>
</ref>
<ref id="bibr102-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vlodavsky</surname><given-names>I</given-names></name>
<name><surname>Beckhove</surname><given-names>P</given-names></name>
<name><surname>Lerner</surname><given-names>I</given-names></name>
<name><surname>Pisano</surname><given-names>C</given-names></name>
<name><surname>Meirovitz</surname><given-names>A</given-names></name>
<name><surname>Ilan</surname><given-names>N</given-names></name>
<name><surname>Elkin</surname><given-names>M</given-names></name>
</person-group>. <year>2011</year>. <article-title>Significance of heparanase in cancer and inflammation</article-title>. <source>Cancer Microenviron</source>. <year>2011</year> <month>Aug</month> <day>3</day>. [<comment>Epub ahead of print</comment>]</citation>
</ref>
<ref id="bibr103-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Woods</surname><given-names>A</given-names></name>
<name><surname>Couchman</surname><given-names>JR</given-names></name>
</person-group>. <year>1994</year>. <article-title>Syndecan-4 heparan sulfate proteoglycan is a selectively enriched and widespread focal adhesion component</article-title>. <source>Mol Cell Biol</source>. <volume>5</volume>:<fpage>183</fpage>–<lpage>192</lpage>.</citation>
</ref>
<ref id="bibr104-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Xiang</surname><given-names>YY</given-names></name>
<name><surname>Ladeda</surname><given-names>V</given-names></name>
<name><surname>Filmus</surname><given-names>J</given-names></name>
</person-group>. <year>2001</year>. <article-title>Glypican-3 expression is silenced in human breast cancer</article-title>. <source>Oncogene</source>. <volume>20</volume>:<fpage>7408</fpage>–<lpage>7412</lpage>.</citation>
</ref>
<ref id="bibr105-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yan</surname><given-names>PS</given-names></name>
<name><surname>Chen</surname><given-names>CM</given-names></name>
<name><surname>Shi</surname><given-names>H</given-names></name>
<name><surname>Rahmatpanah</surname><given-names>F</given-names></name>
<name><surname>Wei</surname><given-names>SH</given-names></name>
<name><surname>Caldwell</surname><given-names>CW</given-names></name>
<name><surname>Huang</surname><given-names>TH</given-names></name>
</person-group>. <year>2001</year>. <article-title>Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays</article-title>. <source>Cancer Res</source>. <volume>61</volume>:<fpage>8375</fpage>–<lpage>8380</lpage>.</citation>
</ref>
<ref id="bibr106-0022155411428469">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zimmermann</surname><given-names>P</given-names></name>
<name><surname>Zhang</surname><given-names>Z</given-names></name>
<name><surname>Degeest</surname><given-names>G</given-names></name>
<name><surname>Mortier</surname><given-names>E</given-names></name>
<name><surname>Leenaerts</surname><given-names>I</given-names></name>
<name><surname>Coomans</surname><given-names>C</given-names></name>
<name><surname>Schulz</surname><given-names>J</given-names></name>
<name><surname>N’Kuli</surname><given-names>F</given-names></name>
<name><surname>Courtoy</surname><given-names>PJ</given-names></name>
<name><surname>David</surname><given-names>G</given-names></name>
</person-group>. <year>2005</year>. <article-title>Syndecan recycling is controlled by syntenin-PIP2 interaction and Arf6</article-title>. <source>Dev Cell</source>. <volume>9</volume>:<fpage>377</fpage>–<lpage>388</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>